daptomycin profile

ID Source	ID
PubMed CID	117590581
MeSH ID	M0026638

Synonym
daptomycin ,
103060-53-3
AKOS025401343
AC-1162

Excerpt	Reference	Relevance
" We conclude that daptomycin is safe and protects kidney cells from tobramycin-induced nephrotoxicity."	( Effects of daptomycin and vancomycin on tobramycin nephrotoxicity in rats. Beauchamp, D; Bergeron, MG; Gourde, P; Pellerin, M; Pettigrew, M, 1990)	0.28
" Safety and tolerability were evaluated by monitoring adverse events (AEs) and laboratory parameters."	( Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Arbeit, RD; Brazier, D; DeBruin, MF; Dvorchik, BH, 2003)	0.32
" The frequency and distribution of adverse events were similar among both treatment groups."	( The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Arbeit, RD; Campanaro, E; Eisenstein, BI; Maki, D; Tally, FP, 2004)	0.32
" Daptomycin was well tolerated, with most adverse events considered to be unrelated to study medication, of mild-to-moderate intensity, and with a frequency and distribution similar to those associated with comparator antibiotics."	( The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. Rybak, MJ, 2006)	0.33
"Although daptomycin is a well-tolerated antibacterial agent, clinicians should consider periodic monitoring of liver function and renal function tests to identify potential adverse effects."	( Daptomycin-induced acute renal and hepatic toxicity without rhabdomyolysis. Abraham, G; Finkelberg, D; Spooner, LM, 2008)	0.35
" No serious adverse events (AE) or deaths occurred during the study."	( Pharmacokinetics and safety of multiple intravenous doses of daptomycin in a Taiwanese adult population. Chang, SC; Huang, YT; Liang, SH; Sheng, WH; Wu, FL, 2009)	0.35
" Daptomycin 4 mg/kg once daily appeared to be effective and safe for treating cellulitis or erysipelas."	( The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas. Bernardo, P; Biermann, EJ; Donfrid, B; Eisenstein, BI; Link, AS; Martone, WJ; Pertel, PE, 2009)	0.35
" In both studies, daptomycin was well tolerated and the majority of treatment-emergent adverse events were of mild intensity and considered to be unrelated to daptomycin."	( Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection. Chakraborty, A; Chaves, RL; Loeffler, J; Roy, S, 2009)	0.35
" Grade 1 adverse events occurred in 22 patients and did not lead to daptomycin discontinuation."	( Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Amodio-Groton, M; Fana, C; Figueroa, DA; Mangini, E; Melchert, A; Segal-Maurer, S; Urban, CM; Vardianos, B; Wehbeh, W, 2009)	0.35
"4%) of the 94 patients experienced 1 or more adverse events or abnormal laboratory value changes possibly related to daptomycin; in 2 (2."	( Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy. Amodio-Groton, MI; Hershberger, E; Lamp, KC; Moise, PA, 2009)	0.35
" Thirty-one (10%) patients experienced adverse events possibly related to daptomycin and the incidence was similar regardless of dose."	( Safety and efficacy of daptomycin in the treatment of osteomyelitis: results from the CORE Registry. Crompton, JA; Lamp, KC; McConnell, SA; North, DS, 2009)	0.35
" The daptomycin group was comparable with the vancomycin group in terms of neutropenia rate, complications, adverse events, length of hospital stay and death."	( Efficacy and safety of daptomycin in the treatment of Gram-positive catheter-related bloodstream infections in cancer patients. Adachi, J; Chaftari, AM; Chemaly, RF; Hachem, R; Jacobson, K; Jiang, Y; Mulanovich, V; Raad, I, 2010)	0.36
" Pharmacokinetic parameters were described, and adverse events were monitored."	( Pharmacokinetics and safety of multiple doses of daptomycin 6 mg/kg in noninfected adults undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Benziger, DP; Cannon, C; Donovan, J; Pertel, PE; Schwab, RJ; Swan, SK; Yankelev, S, 2011)	0.37
" Adverse events were experienced by 71."	( Pharmacokinetics and safety of multiple doses of daptomycin 6 mg/kg in noninfected adults undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Benziger, DP; Cannon, C; Donovan, J; Pertel, PE; Schwab, RJ; Swan, SK; Yankelev, S, 2011)	0.37
"A dose of 200 μg of intravitreal daptomycin appears to be safe and efficacious in a rabbit model of bacterial endophthalmitis."	( Intravitreal daptomycin: a safety and efficacy study. Comer, GM; Elner, VM; Khan, NW; Miller, JB; Reed, DM; Schneider, EW; Zacks, DN, 2011)	0.37
" Thirty-eight adverse events possibly related to daptomycin occurred in 28 patients (7%); increased blood creatine kinase level (7 patients [1."	( Safety of daptomycin in patients receiving hemodialysis. Crompton, JA; Donovan, BJ; Lamp, KC; Mueller, BA; Yankalev, S, 2011)	0.37
" Adverse effects related to daptomycin were detected in nine patients, but none were required to discontinue daptomycin."	( Safety and efficacy of daptomycin for the treatment of hospitalized adult patients in Taiwan with severe staphylococcal infections. Chang, SC; Chen, CJ; Chen, DL; Chou, MU; Ho, MW; Lai, CC; Lee, CM; Liao, CH; Lin, YC; Pong, MY; Sheng, WH; Wang, JT, 2012)	0.38
"The results support daptomycin as an effective and safe treatment for staphylococcal infections in Taiwanese populations."	( Safety and efficacy of daptomycin for the treatment of hospitalized adult patients in Taiwan with severe staphylococcal infections. Chang, SC; Chen, CJ; Chen, DL; Chou, MU; Ho, MW; Lai, CC; Lee, CM; Liao, CH; Lin, YC; Pong, MY; Sheng, WH; Wang, JT, 2012)	0.38
" Based on our data, concomitant administration of daptomycin and statins is safe and is not associated with an increased risk of rhabdomyolysis."	( Safety analysis of high dose (>6 mg/kg/day) daptomycin in patients with concomitant statin therapy. Dueñas-Gutiérrez, C; Garrido-Gomez, J; Hernández-Quero, J; Linares-Palomino, JP; Parra-Ruiz, J; Tomás-Jiménez, C, 2012)	0.38
"The objective of this study was to analyse adverse event (AE) reports submitted to the US FDA as well as published cases to characterize the clinical features and course of EP in daptomycin-treated patients."	( Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports. Kim, PW; Nambiar, S; Pham, TM; Sorbello, AF; Tonning, JM; Wassel, RT, 2012)	0.38
"We searched for EP cases associated with daptomycin administration in the FDA Adverse Event Reporting System (AERS) submitted from 2004 to 2010, and the published literature."	( Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports. Kim, PW; Nambiar, S; Pham, TM; Sorbello, AF; Tonning, JM; Wassel, RT, 2012)	0.38
" In conclusion, daptomycin at 6 and 8 mg/kg given for up to 6 weeks was safe and appeared to be effective in managing staphylococcal PJI using a 2-stage revision arthroplasty technique in a total of 49 patients."	( Randomized controlled trial of the safety and efficacy of Daptomycin versus standard-of-care therapy for management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty. Anastasiou, D; Byren, I; Campanaro, E; Evans, R; Kuropatkin, G; Rege, S; Yankelev, S, 2012)	0.38
" Daptomycin was generally well tolerated; most adverse events were of mild to moderate severity."	( Efficacy and safety of intravenous daptomycin in Japanese patients with skin and soft tissue infections. Aikawa, N; Kato, Y; Kusachi, S; Mikamo, H; Morita, A; Takesue, Y; Tanaka, Y; Tsumori, K; Watanabe, S; Yoshinari, T, 2013)	0.39
" Adverse effects of daptomycin were generally well-tolerated, leading to discontinuation in 3 patients."	( Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patients. Chang, SC; Chen, YC; Cheng, A; Chuang, YC; Lai, CC; Sheng, WH; Wang, JT, 2013)	0.39
"Treatment with high dose daptomycin as salvage therapy was generally effective and safe in Taiwan."	( Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patients. Chang, SC; Chen, YC; Cheng, A; Chuang, YC; Lai, CC; Sheng, WH; Wang, JT, 2013)	0.39
" Investigators assessed adverse events (AEs) using ICH-E2A definitions of seriousness/severity ≤30 days after completing daptomycin."	( Safety of daptomycin in patients completing more than 14 days of therapy: results from the Cubicin® Outcomes Registry and experience. Lamp, KC; Lindfield, KC; Mohr, J; Rege, S; Yoon, M, 2013)	0.39
" Adverse events regardless of relationship to study drug were reported for 11% of patients with cSSTIs and 24% with bacteraemia, most commonly septic shock [7 patients (2%) with cSSTIs and 5 patients (2%) with bacteraemia]."	( Effectiveness and safety of daptomycin in complicated skin and soft-tissue infections and bacteraemia in clinical practice: results of a large non-interventional study. Beiras-Fernandez, A; Chaves, RL; Dohmen, PM; Gonzalez-Ruiz, A; Lehmkuhl, H; Loeffler, J, 2013)	0.39
"Primary safety outcomes included incidence of creatine phosphokinase (CPK) elevations more than 1000 units/L, more than 500 units/L, myalgias, and discontinuation of therapy due to adverse drug events (ADEs)."	( Safety and effectiveness of daptomycin across a hospitalized obese population: results of a multicenter investigation in the southeastern United States. Bland, CM; Bookstaver, PB; Caulder, CR; Faulkner-Fennell, CM; Hartis, C; Qureshi, ZP; Sheldon, MA, 2013)	0.39
" Rates of adverse events (AEs) and serious AEs were similar in both treatment arms; however, discontinuation rates for AEs/serious AEs were lower for daptomycin than for the comparator (3."	( Safety and efficacy of daptomycin as first-line treatment for complicated skin and soft tissue infections in elderly patients: an open-label, multicentre, randomized phase IIIb trial. Bouylout, K; Chaves, RL; Fierlbeck, G; Heep, M; Konychev, A; Kreuter, A; Moritz, RK; Pathan, R; Shulutko, A; Trostmann, U, 2013)	0.39
" The purpose of this study was to compare antimicrobial adverse event rates and associated healthcare interventions and healthcare utilization in patients treated with the two antimicrobials."	( Adverse events, healthcare interventions and healthcare utilization during home infusion therapy with daptomycin and vancomycin: a propensity score-matched cohort study. Gordon, SM; Mason, P; Neuner, E; Nutter, B; O'Rourke, C; Rehm, SJ; Shrestha, NK, 2014)	0.4
" Adverse event, healthcare intervention and healthcare utilization rates during OPAT were compared in the matched cohort using negative binomial regression models."	( Adverse events, healthcare interventions and healthcare utilization during home infusion therapy with daptomycin and vancomycin: a propensity score-matched cohort study. Gordon, SM; Mason, P; Neuner, E; Nutter, B; O'Rourke, C; Rehm, SJ; Shrestha, NK, 2014)	0.4
"Patients receiving daptomycin at home have 60% fewer antimicrobial adverse events and require 80% fewer antimicrobial interventions than similar patients receiving vancomycin."	( Adverse events, healthcare interventions and healthcare utilization during home infusion therapy with daptomycin and vancomycin: a propensity score-matched cohort study. Gordon, SM; Mason, P; Neuner, E; Nutter, B; O'Rourke, C; Rehm, SJ; Shrestha, NK, 2014)	0.4
" No patient required discontinuation of daptomycin because of adverse effects."	( Daptomycin is safe and effective for the treatment of gram-positive cocci infections in solid organ transplantation. Azanza, JR; Cervera, C; Cordero, E; Fariñas, MC; Gavaldà, J; Len, O; Martín-Dávila, P; Montejo, M; Pahissa, A; Ramos, A; Sabé, N; Torre-Cisneros, J, 2014)	0.4
"In summary, daptomycin was a safe and useful treatment for GPC infection in SOT recipients."	( Daptomycin is safe and effective for the treatment of gram-positive cocci infections in solid organ transplantation. Azanza, JR; Cervera, C; Cordero, E; Fariñas, MC; Gavaldà, J; Len, O; Martín-Dávila, P; Montejo, M; Pahissa, A; Ramos, A; Sabé, N; Torre-Cisneros, J, 2014)	0.4
" However, daptomycin tended to have a similar treatment-related adverse events (AEs) incidence in comparison with other antibiotics (OR=1."	( The safety and efficacy of daptomycin versus other antibiotics for skin and soft-tissue infections: a meta-analysis of randomised controlled trials. Chen, XF; Hu, JT; Jiang, LY; Tang, ZH; Wang, SZ; Zhang, C; Zhou, W, 2014)	0.4
" Fewer adverse effects in total, but more CPK elevation effects, were observed in patients treated with daptomycin."	( Efficacy and safety of daptomycin for the treatment of infectious disease: a meta-analysis based on randomized controlled trials. Chen, H; He, W; Wang, H; Zhang, Y; Zhao, C, 2014)	0.4
" In these situations, daptomycin is a safe and effective alternative."	( Daptomycin in the treatment of prosthetic joint infection by Enterococcus faecalis: safety and efficacy of high-dose and prolonged therapy. Del Pozo, JL; Díaz-Rada, P; Quesada, M; Yuste, JR, 2014)	0.4
"4%) represented drug-related adverse effect, but no serious adverse effect was reported."	( [The efficacy and safety of daptomycin for the treatment of Gram-positive bacterial infections in Chinese population]. Gao, H; Li, J; Liu, H; Liu, Z; Shen, J; Wan, X; Wang, A; Zhang, L, 2015)	0.42
"Daptomycin is effective and safe for Chinese patients with serious infections of Gram-positive cocci."	( [The efficacy and safety of daptomycin for the treatment of Gram-positive bacterial infections in Chinese population]. Gao, H; Li, J; Liu, H; Liu, Z; Shen, J; Wan, X; Wang, A; Zhang, L, 2015)	0.42
" The incidence, timing, severity and evolution of adverse events (AEs) were assessed."	( Safety of treatment with high-dose daptomycin in 102 patients with infective endocarditis. Andini, R; Caprioli, R; Cavezza, G; Diana, MV; Durante-Mangoni, E; Mattucci, I; Parrella, A; Senese, A; Trojaniello, C; Utili, R, 2016)	0.43
" Adverse event rates were not significantly different between the two groups."	( Similar efficacy and safety of daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bloodstream infections: a meta-analysis. Chen, D; Ji, L; Liang, L; Patel, K; Zhang, Y; Zhao, M; Zhu, Y, 2016)	0.43
" Two patients (4%) had to be readmitted because of complications; only one patient had an adverse effect related to daptomycin (increase in serum creatine kinase levels), which disappeared after discontinuation (2%)."	( Safety and efficacy of daptomycin in outpatient parenteral antimicrobial therapy: a prospective and multicenter cohort study (DAPTODOM trial). Antón, F; Basterretxea, A; Cervera, C; Cuende, A; García de la María, C; González-Ramallo, V; Miró, JM; Mirón, M; Pajarón, M; Sanclemente, G; Sanroma, P; Segado, A; Sopena, N, 2017)	0.46
"Daptomycin was safe and efficacious in outpatients with Gram-positive bacterial infections and can be administered in 2-minute bolus infusion."	( Safety and efficacy of daptomycin in outpatient parenteral antimicrobial therapy: a prospective and multicenter cohort study (DAPTODOM trial). Antón, F; Basterretxea, A; Cervera, C; Cuende, A; García de la María, C; González-Ramallo, V; Miró, JM; Mirón, M; Pajarón, M; Sanclemente, G; Sanroma, P; Segado, A; Sopena, N, 2017)	0.46
" In both groups, 15% of patients had drug-related adverse events, primarily diarrhea (4% daptomycin, 8% SOC) and increased creatine phosphokinase (4% daptomycin, 0% SOC)."	( Randomized Multicenter Study Comparing Safety and Efficacy of Daptomycin Versus Standard-of-care in Pediatric Patients With Staphylococcal Bacteremia. Arrieta, AC; Bensaci, M; Bokesch, P; Bradley, JS; Du, L; Glasser, C; Grandhi, A; Kartsonis, NA; Patino, H; Popejoy, MW, 2018)	0.48
" Daptomycin in age-adjusted doses is a safe treatment alternative in this setting."	( Randomized Multicenter Study Comparing Safety and Efficacy of Daptomycin Versus Standard-of-care in Pediatric Patients With Staphylococcal Bacteremia. Arrieta, AC; Bensaci, M; Bokesch, P; Bradley, JS; Du, L; Glasser, C; Grandhi, A; Kartsonis, NA; Patino, H; Popejoy, MW, 2018)	0.48
"Outpatient parenteral antimicrobial therapy (OPAT) is a safe and effective alternative to prolonged inpatient stays for patients requiring long-term intravenous antimicrobials, but antimicrobial-associated adverse events remain a significant challenge."	( A retrospective analysis of adverse events among patients receiving daptomycin versus vancomycin during outpatient parenteral antimicrobial therapy. Branch-Elliman, W; LaSalvia, MT; Schrank, GM; Wright, SB, 2018)	0.48
" Additionally, these clinical enhancements of DAP therapy with loading dose were admitted without any enhancements of its adverse effect risks, except alkaline phosphatase elevation, compared with non-loading dose."	( Retrospective study on clinical efficacy and safety for daptomycin intermittent doses with or without loading dose in renal failure patients. Asai, N; Hagihara, M; Kato, H; Koizumi, Y; Mikamo, H; Shibata, Y; Watarai, M; Yamagishi, Y, 2020)	0.56
" No serious adverse events or discontinuation of the drug occurred during the treatment period."	( Efficacy and Safety of High Vs Standard Daptomycin Doses Examined in Chinese Patients With Severe Burn Injuries by Pharmacokinetic Evaluation. Ding, L; Guo, N; Hu, L; Huang, Y; Li, Q; Liu, S; Lv, G; Shao, H; Wu, Y; Yang, Y; Zhu, Y, 2020)	0.56
" The rate of drug-related adverse events was equally distributed in the HD and SD groups (36."	( The Efficacy and Safety of High-dose Daptomycin in the Treatment of Complicated Skin and Soft Tissue Infections in Asians. Chen, FZ; Dong, XM; Guan, YY; Li, QY; Wang, G; Xu, NN; Yao, YY; Zheng, F, 2020)	0.56
"Compared with SD daptomycin, HD daptomycin increased the rate of early clinical stabilization in Asian patients with cSSTIs, whereas the incidence of adverse events did not increase."	( The Efficacy and Safety of High-dose Daptomycin in the Treatment of Complicated Skin and Soft Tissue Infections in Asians. Chen, FZ; Dong, XM; Guan, YY; Li, QY; Wang, G; Xu, NN; Yao, YY; Zheng, F, 2020)	0.56
"Daptomycin is associated with a number of adverse effects including eosinophilic pneumonia, hypersensitivity reaction, myopathy, rhabdomyolysis, headache and transaminitis."	( Safety outcomes with high-dose daptomycin in patients with acute kidney injury and/or end-stage renal disease. Bond, M; Lorenz, AM; Smith, JM; Sobhanie, MM; Vlashyn, OO; Wardlow, L, 2021)	0.62
"To determine the incidence and characteristics of significant adverse effects in patients receiving high-dose daptomycin with severe renal dysfunction."	( Safety outcomes with high-dose daptomycin in patients with acute kidney injury and/or end-stage renal disease. Bond, M; Lorenz, AM; Smith, JM; Sobhanie, MM; Vlashyn, OO; Wardlow, L, 2021)	0.62
" Adverse events (AE) were reported in 42."	( Efficacy and safety of daptomycin in Japanese pediatric participants with complicated skin and soft tissue infections or bacteremia caused by gram-positive cocci. Iwata, S; Koyama, H; Murata, Y, 2022)	0.72
"There is a growing concern about the association between the combined use of daptomycin (DAP) and statins and the occurrence of musculoskeletal adverse events (MAEs), but this remains controversial."	( Association Between Statin Use and Daptomycin-related Musculoskeletal Adverse Events: A Mixed Approach Combining a Meta-analysis and a Disproportionality Analysis. Asada, M; Bando, T; Chuma, M; Goda, M; Hamano, H; Ishizawa, K; Izawa-Ishizawa, Y; Kondo, Y; Miyata, K; Nakamoto, A; Niimura, T; Okada, N; Takechi, K; Tasaki, Y; Yagi, K; Yanagawa, H; Yoshioka, T; Zamami, Y, 2022)	0.72
" Second, we conducted a disproportionality analysis using the US Food and Drug Administration Adverse Events Reporting System (FAERS) to further confirm the results of the meta-analysis and to examine the effect of each type of statin on DAP-related MAEs in a large population."	( Association Between Statin Use and Daptomycin-related Musculoskeletal Adverse Events: A Mixed Approach Combining a Meta-analysis and a Disproportionality Analysis. Asada, M; Bando, T; Chuma, M; Goda, M; Hamano, H; Ishizawa, K; Izawa-Ishizawa, Y; Kondo, Y; Miyata, K; Nakamoto, A; Niimura, T; Okada, N; Takechi, K; Tasaki, Y; Yagi, K; Yanagawa, H; Yoshioka, T; Zamami, Y, 2022)	0.72
"Previous reports on daptomycin's adverse drug reactions (ADRs) have been insufficient, often because of limited data."	( Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system. Chen, JJ; Huo, XC; Wang, F; Wang, SX; Zhao, Q, 2022)	0.72
"The study aimed to promote safe daptomycin prescribing by mining and evaluating the daptomycin ADR signals from the US Food and Drug Administration Adverse Event Reporting System (FAERS)."	( Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system. Chen, JJ; Huo, XC; Wang, F; Wang, SX; Zhao, Q, 2022)	0.72
" Reports of rare adverse events, such as "necrotizing fasciitis and compartment syndrome," have emerged."	( Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system. Chen, JJ; Huo, XC; Wang, F; Wang, SX; Zhao, Q, 2022)	0.72
" Clinical and microbiological responses, adverse events, relapse rate and mortality were considered."	( Efficacy and safety of vancomycin for the treatment of Staphylococcus aureus bacteraemia: a systematic review and meta-analysis. Cai, Y; Xu, J; Yang, T; Yin, H; Zhang, G; Zhang, N, 2023)	0.91
"The efficacy of vancomycin in treating Staphylococcus aureus bacteraemia is still excellent but slightly inferior in adverse events."	( Efficacy and safety of vancomycin for the treatment of Staphylococcus aureus bacteraemia: a systematic review and meta-analysis. Cai, Y; Xu, J; Yang, T; Yin, H; Zhang, G; Zhang, N, 2023)	0.91

Excerpt	Reference	Relevance
" In this thesis pharmacodynamic parameters have been studied after brief exposure of gram-positive bacteria to daptomycin, imipenem or vancomycin and after short exposure of gram-negative bacteria to amikacin, ampicillin, aztreonam, cefepime, cefotaxime, ceftazidime, ceftriaxone, cefuroxime, imipenem, mecillinam, or piperacillin."	( Pharmacodynamic effects of antibiotics. Studies on bacterial morphology, initial killing, postantibiotic effect and effective regrowth time. Hanberger, H, 1992)	0.28
"The purpose of this study was to develop a pharmacodynamic model to describe the dependency of the rate of Staphylococcus aureus killing upon the concentration of daptomycin."	( Investigation of the early killing of Staphylococcus aureus by daptomycin by using an in vitro pharmacodynamic model. Larson, TA; Rotschafer, JC; Toscano, JP; Vance-Bryan, K, 1992)	0.28
" To evaluate the impact of protein on daptomycin activity, a two-chamber in vitro pharmacodynamic model was used to study and compare the interaction between Staphylococcus aureus (clinical isolate) and either daptomycin or vancomycin, each in the presence and absence of physiologic human albumin concentrations."	( Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model. Garrison, MW; Larson, TA; Rotschafer, JC; Toscano, JP; Vance-Bryan, K, 1990)	0.28
"Daptomycin is a new lipopeptide antibiotic for which preliminary pharmacokinetic data in adults have been limited to normal healthy volunteers and patients with renal insufficiency."	( Clinical pharmacokinetics of daptomycin. Novak, RM; Pryka, RD; Rodvold, KA; Wagner, DK, 1990)	0.28
"To describe the pharmacodynamic profile of daptomycin against methicillin-resistant Staphylococcus aureus (MRSA) and Enterococci species based on bacterial density in an immunocompromised mouse thigh infection model."	( Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. Dandekar, PK; Nicolau, DP; Nightingale, CH; Tessier, PR; Williams, P, 2003)	0.32
"The pharmacodynamic (PD) profile of daptomycin was determined against two MRSA, one vancomycin-resistant Enterococcus faecium, and one vancomycin-susceptible Enterococcus faecalis using the immunocompromised murine thigh model."	( Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. Dandekar, PK; Nicolau, DP; Nightingale, CH; Tessier, PR; Williams, P, 2003)	0.32
" aureus (VRSA), an in vitro pharmacodynamic model with simulated endocardial vegetations incorporating protein and a high inoculum was used to simulate daptomycin, linezolid, quinupristin-dalfopristin, and vancomycin against the Michigan VRSA strain."	( Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Brown, WJ; Cha, R; Rybak, MJ, 2003)	0.32
" However, the pharmacodynamic (PD) profile of daptomycin is needed to relate the activity of the drug to biologically achievable concentrations."	( Determination of the pharmacodynamic profile of daptomycin against Streptococcus pneumoniae isolates with varying susceptibility to penicillin in a murine thigh infection model. Dandekar, PK; Nicolau, DP; Nightingale, CH; Tessier, PR; Williams, P; Zhang, C, 2004)	0.32
"We utilized an in vitro pharmacodynamic model to simulate daptomycin regimens of 6 mg/kg/day under controlled conditions of pH, calcium and/or protein."	( Influence of protein binding under controlled conditions on the bactericidal activity of daptomycin in an in vitro pharmacodynamic model. Cha, R; Rybak, MJ, 2004)	0.32
" Further antimicrobial studies that incorporate protein are warranted to assess the influence of protein in the pharmacodynamic evaluation of antimicrobials."	( Influence of protein binding under controlled conditions on the bactericidal activity of daptomycin in an in vitro pharmacodynamic model. Cha, R; Rybak, MJ, 2004)	0.32
" The pharmacokinetic parameters of daptomycin were similar in both groups."	( Moderate liver impairment has no influence on daptomycin pharmacokinetics. Dvorchik, B, 2004)	0.32
" The rate of change of Vz and CL with increasing BMI was greater when these pharmacokinetic parameters were expressed in absolute terms compared to when they were normalized for TBW or ideal body weight."	( The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. Damphousse, D; Dvorchik, BH, 2005)	0.33
"We inoculated an in vitro pharmacodynamic model simultaneously with clinical isolates of methicillin-resistant Staphylococcus aureus and an enterocin-producing enterococcus (vancomycin-resistant Enterococcus faecalis, ampicillin susceptible) at 7 log10 CFU/ml to examine enterocin effects and antimicrobial activity on staphylococci."	( Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model. Chin, JN; LaPlante, KL; Leuthner, KD; Rybak, MJ, 2006)	0.33
" Our search of the literature found no published pediatric pharmacokinetic data."	( Pharmacokinetics of daptomycin in a critically ill adolescent with vancomycin-resistant enterococcal endocarditis. Akins, RL; Haase, MR; Levy, EN, 2006)	0.33
" Other pharmacokinetic parameters measured on day 1 and at steady state were independent of the dose, including the half-life (approximately 8 h), weight-normalized plasma clearance (9 to 10 ml/h/kg), and volume of distribution (approximately 100 ml/kg)."	( Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Benvenuto, M; Benziger, DP; Vigliani, G; Yankelev, S, 2006)	0.33
" Noncompartmental analysis was used to determine the pharmacokinetic parameters, and these values were normalized against TBW, ideal body weight (IBW), and fat-free weight (FFW) for comparison of the two groups."	( Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Anderson, T; Goade, DW; Mercier, RC; Norenberg, JP; Pai, MP; Rodvold, KA; Telepak, RA, 2007)	0.34
" Daptomycin was quantitated from plasma using a validated high performance liquid chromatography method and pharmacokinetic variables determined using a model-dependent approach."	( Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections. Abdel-Rahman, SM; Benziger, DP; Hong, EF; Jacobs, RF; Jafri, HS; Kearns, GL, 2008)	0.35
"76 ml/h/kg), the half-life was 11."	( Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. Bubalo, JS; Cherala, G; Hayes-Lattin, B; Maziarz, R; Munar, MY, 2009)	0.35
"In this report we present pharmacokinetic (Pk) data of daptomycin given intravenously in a peritoneal dialysis patient."	( Pharmacokinetics and dialysate levels of daptomycin given intravenously in a peritoneal dialysis patient. Bode-Boger, SM; Burkhardt, O; Clajus, C; Goedecke, VA; Hiss, M; Kielstein, JT; Martens-Lobenhoffer, J, 2009)	0.35
" A Hill-type pharmacodynamic mathematical model was fitted to the data to characterize the effect."	( Daptomycin pharmacodynamics against Staphylococcus aureus hemB mutants displaying the small colony variant phenotype. Begic, D; Tsuji, BT; von Eiff, C, 2009)	0.35
"In Study 1, pharmacokinetic comparability between the two administration regimens was demonstrated by meeting the bioequivalence criteria for the exposure parameters, AUC(0-t), AUC(0-infinity) and C(max)."	( Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection. Chakraborty, A; Chaves, RL; Loeffler, J; Roy, S, 2009)	0.35
"The similar pharmacokinetic and safety profiles of the two administration regimens suggest that the 2 min iv injection may be a convenient treatment option for both patients and healthcare professionals."	( Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection. Chakraborty, A; Chaves, RL; Loeffler, J; Roy, S, 2009)	0.35
"In an in vitro pharmacodynamic model, linezolid attenuated the activity of aztreonam and ceftazidime against Escherichia coli."	( Evaluating aztreonam and ceftazidime pharmacodynamics with Escherichia coli in combination with daptomycin, linezolid, or vancomycin in an in vitro pharmacodynamic model. LaPlante, KL; Sakoulas, G, 2009)	0.35
" aureus (VRSA), using high and low inocula in a pharmacokinetic in vitro model."	( Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection. Bowker, KE; MacGowan, AP; Noel, AR, 2009)	0.35
" This validated method was successfully applied to a pharmacokinetic study involving intravenous administration of 14mgkg(-1) DPT and 30mgkg(-1) RFM to rabbits."	( Simultaneous quantification of daptomycin and rifampicin in plasma by ultra performance liquid chromatography: Application to a pharmacokinetic study. Bazoti, FN; Fanourgiakis, P; Gikas, E; Perivolioti, E; Roussidis, A; Skoutelis, A; Tsarbopoulos, A, 2010)	0.36
" Individual pharmacokinetic parameters determined by compartmental analysis were used to model trough serum concentrations at 44 and 68 hrs with 6-, 8- and 10-mg/kg post-haemodialysis doses."	( Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients. Churchwell, MD; Gao, L; Heung, M; Mueller, BA; Patel, JH; Salama, NN; Segal, JH, 2010)	0.36
" Daptomycin half-life was 19."	( Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients. Churchwell, MD; Gao, L; Heung, M; Mueller, BA; Patel, JH; Salama, NN; Segal, JH, 2010)	0.36
" A prospective, single-dose pharmacokinetic study was performed in the medical and surgical ICUs of a tertiary care center."	( Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis--a pharmacokinetic study. Bode-Boeger, SM; Burkhardt, O; Eugbers, C; Hafer, C; Haller, H; Joukhadar, C; Kielstein, JT; Knitsch, W; Martens-Lobenhoffer, J; Traunmüller, F, 2010)	0.36
"Key pharmacokinetic parameters like half-life in critically ill patients treated with ED were comparable to healthy controls."	( Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis--a pharmacokinetic study. Bode-Boeger, SM; Burkhardt, O; Eugbers, C; Hafer, C; Haller, H; Joukhadar, C; Kielstein, JT; Knitsch, W; Martens-Lobenhoffer, J; Traunmüller, F, 2010)	0.36
"Prospective, open-label pharmacokinetic study."	( Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. Depestel, DD; Gao, L; Grio, M; Heung, M; Mueller, BA; Salama, NN; Sowinski, KM; Vilay, AM, 2011)	0.37
" Equations describing a two-compartment, open-pharmacokinetic model were fitted to each subject's daptomycin concentration-time data and pharmacokinetic parameters were determined by standard methods."	( Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. Depestel, DD; Gao, L; Grio, M; Heung, M; Mueller, BA; Salama, NN; Sowinski, KM; Vilay, AM, 2011)	0.37
"6 mg/kg (mean ± sd) of daptomycin was administered, resulting in an observed peak concentration of 81."	( Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. Depestel, DD; Gao, L; Grio, M; Heung, M; Mueller, BA; Salama, NN; Sowinski, KM; Vilay, AM, 2011)	0.37
" The present article reviews the pharmacokinetic properties of vancomycin, linezolid, tigecycline and daptomycin."	( Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. Derendorf, H; Estes, KS, 2010)	0.36
" Pharmacokinetic parameters were described, and adverse events were monitored."	( Pharmacokinetics and safety of multiple doses of daptomycin 6 mg/kg in noninfected adults undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Benziger, DP; Cannon, C; Donovan, J; Pertel, PE; Schwab, RJ; Swan, SK; Yankelev, S, 2011)	0.37
" In CAPD subjects, Cmax was 93."	( Pharmacokinetics and safety of multiple doses of daptomycin 6 mg/kg in noninfected adults undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Benziger, DP; Cannon, C; Donovan, J; Pertel, PE; Schwab, RJ; Swan, SK; Yankelev, S, 2011)	0.37
" A series of 9,999-subject Monte Carlo simulations (MCS) was performed to identify HD dosing schemes providing efficacy and toxicity profiles comparable to those obtained for MCS employing the daptomycin population pharmacokinetic (PK) model derived from patients in the Staphylococcus aureus bacteremia-infective endocarditis (SAB-IE) study."	( Use of pharmacokinetic and pharmacodynamic principles to determine optimal administration of daptomycin in patients receiving standardized thrice-weekly hemodialysis. Cardone, K; Drusano, GL; Grabe, DW; Hoy, C; Lodise, TP; Manley, H; Meola, S; Patel, N, 2011)	0.37
"A pharmacokinetic analysis was performed for single intravenous doses of daptomycin 8 or 10 mg/kg in subjects aged 2 to 6 years."	( Single-dose pharmacokinetics and tolerability of daptomycin 8 to 10 mg/kg in children aged 2 to 6 years with suspected or proved Gram-positive infections. Abdel-Rahman, SM; Akins, RL; Benziger, DP; Bradley, JS; Chandorkar, G; Donovan, J; Jacobs, RF, 2011)	0.37
"This study sought to (1) characterize the pharmacokinetic (PK) profile of intravenous (i."	( Pharmacokinetics and pharmacodynamics of intravenous daptomycin during continuous ambulatory peritoneal dialysis. Cardone, KE; Drusano, GL; Grabe, DW; Hoy, CD; Lodise, TP; Manley, HJ; Meola, S; Patel, N, 2011)	0.37
" Pharmacokinetic parameters of daptomycin in serum were calculated using standard noncompartmental methods, and daptomycin was assayed using high-performance liquid chromatography (for serum) or liquid chromatography with mass spectrometry (for CSF)."	( Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections. Chin, JN; Coplin, WM; Edwards, DJ; Kullar, R; Parker, D; Rybak, MJ, 2011)	0.37
"9 μg/ml, half-life [t(1/2)] = 8 h) and DAP at 10 mg/kg/day (fC(max) = 13."	( Characterizing vancomycin-resistant Enterococcus strains with various mechanisms of daptomycin resistance developed in an in vitro pharmacokinetic/pharmacodynamic model. Kaatz, GW; Rose, WE; Rybak, MJ; Steed, ME; Vidaillac, C; Winterfield, P, 2011)	0.37
" In the CVVHD-treated patients, a loading dose of 8 mg/kg lead to Cmax of 87."	( Plasma pharmacokinetics of daptomycin in critically ill patients with renal failure and undergoing CVVHD. Eggers, K; Joukhadar, C; Khadzhynov, D; König, T; Lieker, I; Neumayer, HH; Peters, H; Puhlmann, B; Slowinski, T; Spies, C; Traunmüller, F; Uhrig, A, 2011)	0.37
" Pharmacokinetic parameters were based on 10 sampling timepoints during the first 24 h, and peak and trough samples thereafter."	( Multiple-dose pharmacokinetics of daptomycin during continuous venovenous haemodiafiltration. Dittrich, P; Fuhrmann, V; Meyer, B; Saria, K; Thalhammer, F; Wenisch, JM; Zuba, C, 2012)	0.38
"9 mL/min, and the elimination half-life was 17."	( Multiple-dose pharmacokinetics of daptomycin during continuous venovenous haemodiafiltration. Dittrich, P; Fuhrmann, V; Meyer, B; Saria, K; Thalhammer, F; Wenisch, JM; Zuba, C, 2012)	0.38
"The methodology included the following steps: acquisition of microbiological and pharmacokinetic data, Monte Carlo simulation, estimation of the probability of target attainment (PTA), and calculation of the cumulative fraction of response (CFR)."	( Pharmacokinetic-pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries. Betriu, C; Canut, A; Gascón, AR; Isla, A, 2012)	0.38
" The elimination half-life (t(1/2β)) of daptomycin was independent of the administered dose (38."	( Daptomycin versus vancomycin in a methicillin-resistant Staphylococcus aureus endophthalmitis rabbit model: bactericidal effect, safety, and ocular pharmacokinetics. Bourcier, T; Jehl, F; Lefèvre, S; Marcellin, L; Prévost, G; Saleh, M; Subilia, A, 2012)	0.38
" aureus (MRSA) strain and the antibiotic pharmacodynamic profile against extracellular (broth) and intracellular (human THP-1 monocytes) bacteria."	( Pharmacodynamic evaluation of the activity of antibiotics against hemin- and menadione-dependent small-colony variants of Staphylococcus aureus in models of extracellular (broth) and intracellular (THP-1 monocytes) infections. Becker, K; Denis, O; Garcia, LG; Kahl, BC; Lemaire, S; Proctor, RA; Tulkens, PM; Van Bambeke, F, 2012)	0.38
" The median area under the concentration curve at 24 hours, volume of distribution, total body clearance and half-life of daptomycin were 262."	( Pharmacokinetics and tolerability of single-dose daptomycin in young infants. Benjamin, DK; Cohen-Wolkowiez, M; Hornik, CP; Smith, PB; Watt, KM, 2012)	0.38
"While the pharmacokinetic (PK) properties of daptomycin in hemodialysis (HD) patients have been evaluated previously by three groups, resultant dosing recommendations have varied."	( Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis. Butterfield, JM; Cardone, KE; Grabe, DW; Lodise, TP; Mueller, BA; Patel, N; Salama, NN, 2013)	0.39
"Pharmacokinetic studies of daptomycin in septic patients indicate that pharmacokinetic parameters may be altered."	( Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary? Cassetta, MI; d'Ettorre, G; Falcone, M; Fallani, S; Lappa, A; Novelli, A; Russo, A; Tritapepe, L; Venditti, M, 2013)	0.39
" Our aim was to set up a pharmacodynamic model comparing antibiotic activities against biofilms and examining in parallel their effects on viability and biofilm mass."	( A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms. Bauer, J; Siala, W; Tulkens, PM; Van Bambeke, F, 2013)	0.39
" Population pharmacokinetic, pharmacodynamic and toxicodynamic models were developed based on current literature."	( Pharmacokinetic/pharmacodynamic evaluation of the efficacy and safety of daptomycin against Staphylococcus aureus. Brown, J; Forrest, A; Soon, RL; Tsuji, BT; Turner, SJ, 2013)	0.39
"A population pharmacokinetic analysis of daptomycin was performed based on therapeutic drug monitoring (TDM) data from 58 patients receiving doses of 4-12 mg/kg for the treatment of severe Gram-positive infections."	( Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections. Bocci, G; Danesi, R; Di Paolo, A; Gemignani, G; Karlsson, MO; Menichetti, F; Nielsen, EI; Polillo, M; Tascini, C, 2013)	0.39
"To support daptomycin dosing recommendations in patients with Staphylococcus aureus bacteraemia (SAB) and severe renal impairment using simulations from a population pharmacokinetic model for daptomycin."	( Clinical and pharmacokinetic considerations for the use of daptomycin in patients with Staphylococcus aureus bacteraemia and severe renal impairment. Benziger, D; Chakraborty, A; Chaves, RL; Tannenbaum, S, 2014)	0.4
"A population pharmacokinetic model was developed using 4875 daptomycin plasma concentrations from 442 subjects."	( Clinical and pharmacokinetic considerations for the use of daptomycin in patients with Staphylococcus aureus bacteraemia and severe renal impairment. Benziger, D; Chakraborty, A; Chaves, RL; Tannenbaum, S, 2014)	0.4
" A standard population pharmacokinetic model was used to simulate 5,000 daptomycin concentration-time profiles after 5 doses of 6 mg/kg of body weight/day (0."	( Simplified equations using two concentrations to calculate area under the curve for antimicrobials with concentration-dependent pharmacodynamics: daptomycin as a motivating example. Falcone, M; Novelli, A; Pai, MP; Russo, A; Venditti, M, 2014)	0.4
"In this phase 1, multicenter, open-label, noncomparative pharmacokinetic and safety study, patients were enrolled in 3 age groups: 3-6, 7-12 and 13-24 months."	( Single-dose pharmacokinetics of daptomycin in pediatric patients 3-24 months of age. Benziger, D; Bokesch, P; Bradley, JS; Jacobs, R, 2014)	0.4
" Because no existing studies of this nature were available, Cmax following daptomycin 6 mg/kg/10 s multiple-dose bolus injections was simulated."	( Evaluation of the safety, tolerability, and pharmacokinetics of a single bolus injection of daptomycin in healthy Japanese subjects. Aoki, I; Aso, M; Ishikawa, K; Wakana, A; Yoshinari, T, 2015)	0.42
"The clinical development of FtsZ-targeting benzamide compounds like PC190723 has been limited by poor drug-like and pharmacokinetic properties."	( TXA709, an FtsZ-Targeting Benzamide Prodrug with Improved Pharmacokinetics and Enhanced In Vivo Efficacy against Methicillin-Resistant Staphylococcus aureus. Kaul, M; LaVoie, EJ; Lyu, YL; Mark, L; Parhi, AK; Pawlak, J; Pilch, DS; Saravolatz, LD; Saravolatz, S; Weinstein, MP; Zhang, Y, 2015)	0.42
"The relationships between pharmacokinetic (PK)/pharmacodynamic (PD) indices and outcomes were investigated in patients with skin and soft tissue infection (SSTI) who received daptomycin at 4 mg/kg/day."	( Correlation between pharmacokinetic/pharmacodynamic indices and clinical outcomes in Japanese patients with skin and soft tissue infections treated with daptomycin: analysis of a phase III study. Aikawa, N; Ishii, M; Kusachi, S; Mikamo, H; Takahashi, K; Takesue, Y; Watanabe, S; Yoshinari, T, 2015)	0.42
"Pharmacodynamic activity in antibiotic combinations of daptomycin, vancomycin, and linezolid was investigated in a 48-h in vitro pharmacodynamic model."	( Observed Antagonistic Effect of Linezolid on Daptomycin or Vancomycin Activity against Biofilm-Forming Methicillin-Resistant Staphylococcus aureus in an In Vitro Pharmacodynamic Model. LaPlante, KL; Luther, MK, 2015)	0.42
"The interindividual and intraindividual variabilities in daptomycin pharmacokinetics were investigated in 23 patients (69 pharmacokinetic profiles) who were treated for several months for bone and joint infections."	( Pharmacokinetic Variability of Daptomycin during Prolonged Therapy for Bone and Joint Infections. Ader, F; Chidiac, C; Ferry, T; Gagnieu, MC; Goutelle, S; Laurent, F; Lustig, S; Roux, S; Valour, F, 2016)	0.43
" However, future studies need to address several issues to determine the optimal dose and various pharmacokinetic parameters in different pediatric age groups."	( Clinical Effectiveness, Safety Profile, and Pharmacokinetics of Daptomycin in Pediatric Patients: A Systematic Review. Dakoutrou, M; Karageorgos, SA; Miligkos, M; Tsioutis, C, 2016)	0.43
"The objective of this population pharmacokinetic (PK) analysis was to provide guidance for the dosing interval of daptomycin in patients undergoing continuous renal replacement therapy (CRRT)."	( Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapy. Chaves, RL; Corti, N; Hamed, K; Khadzhynov, D; Levi, M; Peters, H; Xu, X, 2017)	0.46
" The protocol will further continue to assess whether a higher dose achieves the pharmacokinetic objectives."	( Pharmacokinetics of Intraperitoneal Daptomycin in Patients with Peritoneal Dialysis-Related Peritonitis. Bouvier, N; Cattoir, V; Debruyne, D; Ficheux, M; Fournel, F; Lobbedez, T; Loilier, M; Morello, R; Parienti, JJ; Peyro Saint Paul, L; Verdon, R, 2017)	0.46
"5, 1, 2, 3, 5, 7, 9 and 12 h after dosing) to assess the pharmacokinetic profile of daptomycin."	( Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies. Candoni, A; Cojutti, PG; Fanin, R; Hope, W; Lazzarotto, D; Pea, F; Ramos-Martin, V; Zannier, ME, 2017)	0.46
" Pharmacokinetic parameters after single oral administration of optimized proliposomal formulation indicated a significant increase in oral bioavailability of DAP administered as SPC-SA proliposomes when compared to drug solution."	( Daptomycin Proliposomes for Oral Delivery: Formulation, Characterization, and In Vivo Pharmacokinetics. Arregui, JR; Betageri, GV; Kovvasu, SP, 2018)	0.48
" However, pharmacodynamic targets associated with positive patient outcomes are undefined."	( Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint. Aitken, SL; Arias, CA; Avery, LM; Britt, NS; Chong, PP; Contreras, GA; DiPippo, AJ; Egli, A; Kuti, JL; Nicolau, DP; Rybak, MJ; Wang, JT; Weisser, M; Zasowski, EJ, 2019)	0.51
" Daptomycin exposures were calculated using a published population pharmacokinetic model."	( Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint. Aitken, SL; Arias, CA; Avery, LM; Britt, NS; Chong, PP; Contreras, GA; DiPippo, AJ; Egli, A; Kuti, JL; Nicolau, DP; Rybak, MJ; Wang, JT; Weisser, M; Zasowski, EJ, 2019)	0.51
" Total and unbound plasma concentrations and urine concentrations of daptomycin were analysed simultaneously following a population pharmacokinetic approach."	( Population pharmacokinetics of daptomycin in critically ill patients with various degrees of renal impairment. Asehnoune, K; Barbaz, M; Couet, W; Ferrandière, M; Gaillard, T; Grégoire, N; Lasocki, S; Launey, Y; Marchand, S; Mimoz, O; Seguin, P; Vourc'h, M, 2019)	0.51
" Simulations performed with the final model examined the influence of covariates on the probability to achieve pharmacodynamic (PD) targets."	( Genetic polymorphisms of ABCB1 (P-glycoprotein) as a covariate influencing daptomycin pharmacokinetics: a population analysis in patients with bone and joint infection. Becker, A; Bricca, R; Chidiac, C; Conrad, A; Ferry, T; Gagnieu, MC; Goutelle, S; Laurent, F; Roux, S; Triffault-Fillit, C; Valour, F, 2019)	0.51
" Exposures were calculated using a published population pharmacokinetic model based on creatinine clearance, 90% protein binding and daptomycin Etest MIC."	( Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia. Aitken, SL; Arias, CA; Avery, LM; Britt, NS; Chong, PP; Contreras, GA; DiPippo, AJ; Egli, A; Kuti, JL; Nicolau, DP; Rybak, MJ; Wang, JT; Weisser, M; Zasowski, EJ, 2019)	0.51
" In the current study relationships between DAP Cmin and CPK elevation were investigated, and optimal DAP doses were determined."	( Observational study to determine the optimal dose of daptomycin based on pharmacokinetic/pharmacodynamic analysis. Katsumata, T; Kawanishi, F; Nakano, T; Nishihara, M; Oda, K; Ooi, Y; Shibata, Y; Suzuki, K; Uchida, T; Ukimura, A; Yamada, T; Yoshida, M, 2020)	0.56
" In silico pharmacodynamic models based on stochastic simulations (Monte Carlo) are important tools to estimate best antimicrobial regimens in different scenarios."	( Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration. Cuba, GT; da Costa, TM; Dos Santos, KRN; Kiffer, CRV; Morgado, PGM; Nicolau, DP; Nouér, SA, 2020)	0.56
" The study retrospectively analyzed 10 patients with severe burn injuries, using pharmacokinetic (PK) and pharmacodynamic (PD) evaluations of daptomycin doses given to combat serious infections."	( Efficacy and Safety of High Vs Standard Daptomycin Doses Examined in Chinese Patients With Severe Burn Injuries by Pharmacokinetic Evaluation. Ding, L; Guo, N; Hu, L; Huang, Y; Li, Q; Liu, S; Lv, G; Shao, H; Wu, Y; Yang, Y; Zhu, Y, 2020)	0.56
" Monte Carlo simulations (MCSs) were conducted using pharmacokinetic (PK) parameters and pharmacodynamic (PD) data to determine the probabilities of target attainment and cumulative fractions of response in terms of area under the concentration curve/minimum inhibition concentration (MIC) targets of daptomycin."	( Pharmacokinetic/Pharmacodynamic Analysis of Daptomycin Against Staphylococcus aureus and Enterococcus faecium in Pediatric Patients by Monte Carlo Simulation. Li, X; Wei, XC; Xiao, X; Zhao, MF, 2020)	0.56
"Individual concentration data of 32 CRRT subjects pooled from previously published studies were used to construct the population pharmacokinetic model for daptomycin."	( Population pharmacokinetics and dosing considerations of daptomycin in critically ill patients undergoing continuous renal replacement therapy. Cheng, Z; Li, S; Xie, F, 2020)	0.56
"We performed population pharmacokinetic analysis of the unbound concentrations of daptomycin."	( Population Pharmacokinetic Analysis and Dosing Optimization Based on Unbound Daptomycin Concentration and Cystatin C in Nonobese Elderly Patients with Hypoalbuminemia and Chronic Kidney Disease. Enoki, Y; Higashita, R; Ito, H; Koshioka, S; Kunika, N; Kurata, T; Matsumoto, K; Nagumo, F; Samura, M; Taguchi, K; Takada, K; Tanikawa, K; Uchida, M; Yamamoto, R, 2021)	0.62
"In the population pharmacokinetic analysis of 25 patients aged ≥65 years, the two-compartment model using eGFRcys and age as covariates of clearance in central compartment of unbound daptomycin were optimal."	( Population Pharmacokinetic Analysis and Dosing Optimization Based on Unbound Daptomycin Concentration and Cystatin C in Nonobese Elderly Patients with Hypoalbuminemia and Chronic Kidney Disease. Enoki, Y; Higashita, R; Ito, H; Koshioka, S; Kunika, N; Kurata, T; Matsumoto, K; Nagumo, F; Samura, M; Taguchi, K; Takada, K; Tanikawa, K; Uchida, M; Yamamoto, R, 2021)	0.62
" Current guidelines recommend higher daptomycin doses (8-10 mg/kg) for severe infections; however, pharmacokinetic (PK) and pharmacodynamic-based dosing strategies are still limited."	( Simplified daptomycin dosing regimen for adult patients with methicillin-resistant Staphylococcus aureus infections based on population pharmacokinetic analysis. Egashira, N; Ieiri, I; Kitaichi, K; Maeshiro, Y; Miyake, N; Nishida, R; Oida, Y; Shimono, N; Soda, M; Yamada, T; Yamashita, Y, 2022)	0.72
" We sought to establish a physiologically based pharmacokinetic (PBPK) model of daptomycin to describe the dynamics of daptomycin disposition in bone and skin tissue."	( Daptomycin Physiology-Based Pharmacokinetic Modeling to Predict Drug Exposure and Pharmacodynamics in Skin and Bone Tissues. Bourguignon, L; Ferry, T; Garreau, R; Goutelle, S; Grillon, A; Jehl, F; Montange, D, 2022)	0.72
"5 and 2 for all pharmacokinetic quantities in blood, skin and bone tissues."	( Daptomycin Physiology-Based Pharmacokinetic Modeling to Predict Drug Exposure and Pharmacodynamics in Skin and Bone Tissues. Bourguignon, L; Ferry, T; Garreau, R; Goutelle, S; Grillon, A; Jehl, F; Montange, D, 2022)	0.72
" We developed a population pharmacokinetic model to predict both total and unbound daptomycin concentrations."	( Population Pharmacokinetic Model for Unbound Concentrations of Daptomycin in Patients with MRSA Including Patients Undergoing Hemodialysis. Holford, N; Kasai, H; Kawasuji, H; Ogami, C; Takahashi, S; To, H; Tsuji, Y; Yamamoto, Y, 2023)	0.91
"Physiologically based pharmacokinetic models were developed from pharmacokinetic studies of healthy adults, geriatric, paediatric, obese and RI patients."	( Physiologically based pharmacokinetic modelling to inform combination dosing regimens of ceftaroline and daptomycin in special populations. Annaert, P; Martins, FS; Martins, JES; Severino, P; Sy, SKB, 2023)	0.91
"Our work illustrates how physiologically based pharmacokinetic modelling can inform appropriate dosing of adult and paediatric patients and thereby enable prediction of target attainment in the patients during multitherapies."	( Physiologically based pharmacokinetic modelling to inform combination dosing regimens of ceftaroline and daptomycin in special populations. Annaert, P; Martins, FS; Martins, JES; Severino, P; Sy, SKB, 2023)	0.91

Excerpt	Reference	Relevance
"Using an experimental endocarditis model, we studied the activity of daptomycin used alone or in combination with gentamicin against an Enterococcus faecium strain that was highly resistant to glycopeptides and susceptible to gentamicin."	( Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium. Carbon, C; Caron, F; Cremieux, AC; Gutmann, L; Kitzis, MD; Lemeland, JF; Maziere, B; Saleh-Mghir, A; Vallois, JM, 1992)	0.28
" The bactericidal effect obtained with daptomycin in combination with aminoglycosides suggest that further evaluation of these combinations in enterococcal endocarditis could have a clinical interest if this bactericidal effect was confirmed by in vivo studies."	( [Bactericidal activity of daptomycin and vancomycin alone or in combination with tobramycin, netilmicin or ampicillin against enterococcus]. Cordin, X; Duez, JM; Kazmierczak, A; Péchinot, A; Siébor, E, 1989)	0.28
"The antibacterial activity of LY146032 alone and in combination with other drugs was assayed against gram-positive isolates."	( In vitro activity of LY146032 alone and in combination with other antibiotics against gram-positive bacteria. Debbia, E; Pesce, A; Schito, GC, 1988)	0.27
" Daptomycin in combination with ampicillin, rifampin, and gentamicin was tested against enterococci; daptomycin in combination with ampicillin-sulbactam, piperacillin-tazobactam, and ticarcillin-clavulanate was tested against staphylococci."	( In vitro activity of daptomycin alone and in combination with various antimicrobials against Gram-positive cocci. Aydemir, S; Cilli, F; Tunger, A, 2006)	0.33
" Daptomycin sub-MICs combined with gentamicin concentrations lower than the MIC yielded synergy in 34 (68%) of the 50 strains."	( Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology. Appelbaum, PC; Credito, K; Lin, G, 2007)	0.34
"3 log(10) CFU/ml, whereas in combination with rifampin, a reduction in the counts of >6 log(10) CFU/ml was observed."	( Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Baldoni, D; Haschke, M; John, AK; Rentsch, K; Schaerli, P; Trampuz, A; Zimmerli, W, 2009)	0.35
" We investigated the effects of vancomycin (VAN), daptomycin (DAP), fosfomycin (FOS), tigecycline (TGC), and ceftriaxone (CRX), alone and in combination with azithromycin (AZI), on established biofilms of Staphylococcus epidermidis."	( Effects of azithromycin in combination with vancomycin, daptomycin, fosfomycin, tigecycline, and ceftriaxone on Staphylococcus epidermidis biofilms. Graninger, W; Hajdu, S; Hirschl, AM; Holinka, J; Lassnigg, AM; Presterl, E, 2009)	0.35
" The purpose of the present study was to quantify the biofilm formation of methicillin (meticillin)-resistant Staphylococcus aureus (MRSA) isolates obtained from patients with IE and to evaluate the in vitro activities of daptomycin and vancomycin alone and in combination with rifampin (rifampicin) or gentamicin while monitoring the isolates for the development of resistance."	( Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis. LaPlante, KL; Woodmansee, S, 2009)	0.35
" aureus (four MRSA and two GISA) and four strains of enterococci (two Enterococcus faecalis and two Enterococcus faecium) were serially exposed in broth to two-fold stepwise increasing concentrations of daptomycin alone or in combination with a fixed concentration [0."	( In vitro prevention of the emergence of daptomycin resistance in Staphylococcus aureus and enterococci following combination with amoxicillin/clavulanic acid or ampicillin. Entenza, JM; Giddey, M; Moreillon, P; Vouillamoz, J, 2010)	0.36
" Simulated regimens included vancomycin (VAN) plus rifampin (RIF), moxifloxacin (MOX), and high doses (10 mg/kg of body weight/day) of daptomycin (DAP) alone or combined with RIF or clarithromycin (CLA)."	( Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. Parra-Ruiz, J; Rose, WE; Rybak, MJ; Vidaillac, C, 2010)	0.36
" Daptomycin in combination with rifampicin needs to be assessed in bone infection."	( Efficacy of daptomycin combined with rifampicin for the treatment of experimental meticillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitis. Amador, G; Asseray, N; Caillon, J; Jacqueline, C; Le Mabecque, V; Lefebvre, M; Miegeville, A; Potel, G, 2010)	0.36
" The aim of this study was to evaluate the efficacies of daptomycin at usual and high doses (equivalent to 6 and 10 mg/kg of body weight/day, respectively, in humans) and in combination with rifampin and to compare the activities to those of conventional anti-MRSA therapies."	( Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Ariza, J; Cabellos, C; Cabo, J; Euba, G; Garrigós, C; Murillo, O; Tubau, F; Verdaguer, R, 2010)	0.36
" Synergy was demonstrated when HSM1 was combined with vancomycin and daptomycin."	( In vitro activity and in vivo efficacy of the saponin diosgenyl 2-amino-2-deoxy-β-D-glucopyranoside hydrochloride (HSM1) alone and in combination with daptomycin and vancomycin against Gram-positive cocci. Brescini, L; Cirioni, O; Dawgul, M; Ghiselli, R; Giacometti, A; Guerrieri, M; Kamysz, W; Myszka, H; Orlando, F; Silvestri, C, 2011)	0.37
" In conclusion, our results suggested a strong activity of tigecycline alone and in combination with other antimicrobial agents against multi-resistant Gram-positive organisms isolated from wound infections."	( In vitro activity and in vivo efficacy of tigecycline alone and in combination with daptomycin and rifampin against Gram-positive cocci isolated from surgical wound infection. Arzeni, D; Brescini, L; Cirioni, O; Ganzetti, G; Ghiselli, R; Giacometti, A; Guerrieri, M; Offidani, A; Orlando, F; Provinciali, M; Silvestri, C; Simonetti, O; Staffolani, S, 2012)	0.38
" This investigation assessed risk for myopathy in patients receiving treatment with a statin in combination with daptomycin, a medication also associated with muscle injury."	( Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability. Barber, GR; Barron, MA; Golightly, LK; Page, RL, 2013)	0.39
" Risk of muscle injury therefore appears to be no greater when a statin is administered with daptomycin than when either medication is used alone."	( Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability. Barber, GR; Barron, MA; Golightly, LK; Page, RL, 2013)	0.39
"Treatment of Gram-positive osteoarticular infections requires an adequate surgical approach combined with intensive antimicrobial therapy."	( The safety and efficacy of high-dose daptomycin combined with rifampicin for the treatment of Gram-positive osteoarticular infections. Garbino, J; Hoffmeyer, P; Jugun, K; Lew, D; Pagani, L; Uçkay, I; Vaudaux, P, 2013)	0.39
"The activity of colistin in combination with daptomycin was assessed using 30 Gram-negative type strains and multidrug-resistant isolates with defined mechanisms of resistance."	( In vitro activity of daptomycin in combination with low-dose colistin against a diverse collection of Gram-negative bacterial pathogens. Hornsey, M; Phee, L; Wareham, DW, 2013)	0.39
" Daptomycin, in combination with other antibiotics, has been successfully used in the treatment of these infections, with the aims of resulting in reducing the prevention of antimicrobial resistance and increased killing compared with daptomycin monotherapy."	( Daptomycin in combination with other antibiotics for the treatment of complicated methicillin-resistant Staphylococcus aureus bacteremia. Dhand, A; Sakoulas, G, 2014)	0.4
"There are limited clinical data on the use of daptomycin in combination with other antibiotics."	( Daptomycin in combination with other antibiotics for the treatment of complicated methicillin-resistant Staphylococcus aureus bacteremia. Dhand, A; Sakoulas, G, 2014)	0.4
"Use of daptomycin in combination with other antibiotics, especially β-lactams, offers a promising treatment option for complicated MRSA bacteremia in which emergence of resistance during treatment may be anticipated."	( Daptomycin in combination with other antibiotics for the treatment of complicated methicillin-resistant Staphylococcus aureus bacteremia. Dhand, A; Sakoulas, G, 2014)	0.4
" Of studied drugs, daptomycin was the common element in the most active regimens when combined with doxycycline plus either beta-lactams (cefoperazone or carbenicillin) or an energy inhibitor (clofazimine)."	( Drug combinations against Borrelia burgdorferi persisters in vitro: eradication achieved by using daptomycin, cefoperazone and doxycycline. Auwaerter, PG; Feng, J; Zhang, Y, 2015)	0.42
" This study systematically evaluated by in vitro time-kill studies the effect of daptomycin in combination with ampicillin, cefazolin, ceftriaxone, ceftaroline, ertapenem, gentamicin, tigecycline, and rifampin, for a collection of 9 daptomycin-NS enterococci that exhibited a broad range of MICs and different resistance-conferring mutations."	( In vitro activity of daptomycin in combination with β-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci. Carvalho, M; Charlton, CL; Hindler, JA; Humphries, R; Kelesidis, T; Miller, SA; Nizet, V; Nonejuie, P; Pogliano, J; Sakoulas, G; Wong-Beringer, A, 2015)	0.42
" aureus activity of P128 alone and in combination with standard-of-care antibiotics on planktonic and biofilm-embedded cells."	( Antibiofilm Activity and Synergistic Inhibition of Staphylococcus aureus Biofilms by Bactericidal Protein P128 in Combination with Antibiotics. Desai, S; Nair, S; Poonacha, N; Sharma, U; Vipra, A, 2016)	0.43
"This study aimed to explore daptomycin combined with fosfomycin or rifampin against the planktonic and adherent linezolid-resistant isolates of Enterococcus faecalis."	( In vitro activities of daptomycin combined with fosfomycin or rifampin on planktonic and adherent linezolid-resistant isolates of Enterococcus faecalis. Chen, Z; Deng, QW; Jiang, SB; Lin, ZW; Qi, GB; Qu, D; Sun, X; Tu, HP; Wu, Y; Yu, ZJ; Zheng, JX, 2019)	0.51
"Daptomycin is commonly prescribed in combination with other antibiotics for treatment of enterococcal bacteraemia."	( Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia. Aitken, SL; Arias, CA; Avery, LM; Britt, NS; Chong, PP; Contreras, GA; DiPippo, AJ; Egli, A; Kuti, JL; Nicolau, DP; Rybak, MJ; Wang, JT; Weisser, M; Zasowski, EJ, 2019)	0.51
" In the in vivo EE model, the following antibiotic combinations were evaluated: cloxacillin (2 g/4 h) alone or combined with gentamicin (1 mg/kg/8 h) or daptomycin (6 mg/kg once daily); and daptomycin (6 mg/kg/day) alone or combined with fosfomycin (2 g/6 h)."	( Cloxacillin or fosfomycin plus daptomycin combinations are more active than cloxacillin monotherapy or combined with gentamicin against MSSA in a rabbit model of experimental endocarditis. Almela, M; Ambrosioni, J; Cañas, MA; Castañeda, X; Falces, C; Fuster, D; García-de-la-Mària, C; García-González, J; Gasch, O; Hernández-Meneses, M; Llopis, J; Marco, F; Miró, JM; Moreno, A; Pericàs, JM; Quintana, E; Sandoval, E; Soy, D; Téllez, A; Tolosana, JM; Vidal, B, 2020)	0.56
" When given for four daily doses, both lysin dose regimens in combination with daptomycin sterilized all target tissues."	( Efficacy of Antistaphylococcal Lysin LSVT-1701 in Combination with Daptomycin in Experimental Left-Sided Infective Endocarditis Due to Methicillin-Resistant Staphylococcus aureus. Abdelhady, W; Bayer, AS; Borroto-Esoda, K; Gaukel, E; Huang, DB; Kerzee, N; Lowry, S; Xiong, YQ, 2021)	0.62
" faecium with monotherapy or its combination with daptomycin by time-killing assay."	( In vitro activities of thiazolidione derivatives combined with daptomycin against clinical Enterococcus faecium strains. Chen, J; Chen, Z; Deng, Q; Qu, D; Tang, Y; Wu, Y; Xiong, Y; Yu, Z; Zhao, Y; Zheng, J, 2022)	0.72

Excerpt	Reference	Relevance
" The good peritoneal bioavailability of DAP was quantitatively established, suggesting that IP administration could also be used as an alternate route for patients with damaged venous access."	( Pharmacokinetics of Intraperitoneal Daptomycin in Patients with Peritoneal Dialysis-Related Peritonitis. Bouvier, N; Cattoir, V; Debruyne, D; Ficheux, M; Fournel, F; Lobbedez, T; Loilier, M; Morello, R; Parienti, JJ; Peyro Saint Paul, L; Verdon, R, 2017)	0.46
" Pharmacokinetic parameters after single oral administration of optimized proliposomal formulation indicated a significant increase in oral bioavailability of DAP administered as SPC-SA proliposomes when compared to drug solution."	( Daptomycin Proliposomes for Oral Delivery: Formulation, Characterization, and In Vivo Pharmacokinetics. Arregui, JR; Betageri, GV; Kovvasu, SP, 2018)	0.48
" Although some of the biological factors have been reported that regulate intestinal permeation of cyclic peptides, the influence of the mucus barrier, a major hurdle to epithelial drug delivery, on cyclic peptide bioavailability is unclear."	( The lipophilic cyclic peptide cyclosporin A induces aggregation of gel-forming mucins. Kishimoto, H; Ridley, C; Thornton, DJ, 2022)	0.72
"This study is an economic analysis seeking to examine cost savings that may be accrued from usage of oral linezolid in place of OPAT IV daptomycin in patients requiring prolonged courses of IV or highly bioavailable oral antibiotic therapy."	( A cost minimisation analysis comparing oral linezolid and intravenous daptomycin administered via an outpatient parenteral antibiotic therapy programme in patients requiring prolonged antibiotic courses. Faller, E; Jackson, A, 2023)	0.91

Excerpt	Relevance	Reference
" Animals infected with strain SF-195 received 5 days of no therapy, ampicillin, ampicillin-gentamicin, vancomycin, or daptomycin (all at the dosage regimens described above)."	( Comparison of daptomycin, vancomycin, and ampicillin-gentamicin for treatment of experimental endocarditis caused by penicillin-resistant enterococci. Bayer, AS; Eliopoulos, GM; Grayson, ML; Ramos, MC, 1992)	0.28
" High protein binding of daptomycin (> 90%) and the lower-than-expected concentrations in serum with the dosage regimen of 3 mg/kg of body weight every 12 h may have contributed to these failures."	( In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Bailey, EM; Kaatz, GW; Lamp, KC; Rybak, MJ, 1992)	0.28
" Two dosage regimens of each drug were used: 10 mg/kg and 5 mg/kg administered every 12 h for 14 days."	( Daptomycin versus vancomycin treatment for Staphylococcus aureus bacteremia in a murine model. Avent, K; Cobbs, G; Dill, R; Graves, A; Lyon, D; Smith, K, 1990)	0.28
" It is likely that the clinical efficacy of daptomycin in humans would be enhanced by higher dosing than has been studied to date."	( Effect of human serum on the bactericidal activity of daptomycin and vancomycin against staphylococcal and enterococcal isolates as determined by time-kill kinetic studies. Stratton, CW; Weeks, LS, )	0.13
" The sponsor of daptomycin is currently reevaluating the recommendation and may be revising their dosage guidelines in the future."	( Suboptimal effect of daptomycin in the treatment of bacteremias. Crossley, KB; Garrison, MW; Rotschafer, JC, 1989)	0.28
" To guide the clinical dosing regimen with the potential for the least effect on skeletal muscle, two studies were conducted with dogs to compare the effects of repeated intravenous administration every 24 h versus every 8 h for 20 days."	( Once-daily dosing in dogs optimizes daptomycin safety. Berman, CL; Kirkpatrick, JB; Lai, JJ; Oleson, FB; Regan, KS; Tally, FP, 2000)	0.31
" Among them, only the once-daily dosing of aminoglycosides has been brought to the clinic and physicians are now increasingly adopting this approach to reduce the toxicity of these agents."	( Aminoglycoside nephrotoxicity: do time and frequency of administration matter? Beauchamp, D; Labrecque, G, 2001)	0.31
" For all three doses, plasma daptomycin concentrations were consistent and predictable throughout the dosing interval."	( Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Arbeit, RD; Brazier, D; DeBruin, MF; Dvorchik, BH, 2003)	0.32
" We employed pharmacodynamic modeling to determine a once-daily dosing regimen of daptomycin that correlates to pharmacodynamic endpoints for different resistant gram-positive clinical strains."	( Daptomycin dose-effect relationship against resistant gram-positive organisms. Cha, R; Grucz, RG; Rybak, MJ, 2003)	0.32
" Drug dosage should be adapted to obtain inflammatory fluid levels of daptomycin minimizing emergence of resistant subpopulations."	( Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus. Bisognano, C; Francois, P; Lew, DP; Li, D; Schrenzel, J; Vaudaux, P, 2003)	0.32
" In pursuit of potential clinical dosing regimens for endocarditis, we evaluated two, once-daily daptomycin regimens against multiple, drug-resistant Gram-positive pathogens."	( Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Cha, R; Rybak, MJ, 2003)	0.32
"At the conclusion of this learning activity, participants should be familiar with the modes of action, clinical indications, dosage regimens, and contraindications and cautions for several novel antibacterial agents for skin and skin structure infections."	( Novel antibacterial agents for skin and skin structure infections. Schweiger, ES; Weinberg, JM, 2004)	0.32
" This analysis supports the dosing of daptomycin on a milligram-per-kilogram-of-body-weight basis and suggests that modified dosing regimens are indicated for patients with severe renal disease and for those undergoing dialysis."	( Population pharmacokinetics of daptomycin. Arbeit, RD; Chung, J; Dvorchik, B; Kastrissios, H; Knebel, W; Liu, S, 2004)	0.32
" Once-daily dosing has diminished the preclinical incidence of myopathy."	( Muscle pain associated with daptomycin. Louie, KR; Malesker, MA; Smith, PW; Veligandla, SR, 2004)	0.32
" Human therapeutic dosing regimens for nafcillin, daptomycin, vancomycin, linezolid, and gentamicin were simulated."	( Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. LaPlante, KL; Rybak, MJ, 2004)	0.32
" Daptomycin may be dosed based on total body weight, and no adjustment in daptomycin dose or dose regimen should be required based solely on obesity."	( The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. Damphousse, D; Dvorchik, BH, 2005)	0.33
" No dosage adjustment appears to be necessary for mild to moderate hepatic impairment."	( Daptomycin: a cyclic lipopeptide antimicrobial agent. Fung, HB; Jeu, L, 2004)	0.32
" A dosage of 4 mg/kg intravenous once a day has been shown to be efficacious in two evaluator-blinded trials of complicated skin and soft tissue infections with clinical success rates similar for daptomycin and comparators (vancomycin or penicillinase-resistant penicillins)."	( The need for new therapeutic agents: what is the pipeline? Shah, PM, 2005)	0.33
"The development, activity, pharmacokinetics, pharmacodynamics, clinical efficacy, adverse effects, and dosage and administration of daptomycin are reviewed."	( Daptomycin: a novel cyclic lipopeptide antimicrobial. Danziger, LH; Fernández, C; Rodvold, KA; Schriever, CA, 2005)	0.33
" Human therapeutic dosing regimens for daptomycin (6 and 8 mg/kg of body weight), vancomycin, and gentamicin were simulated."	( Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Rybak, MJ; Tsuji, BT, 2005)	0.33
"To report a case in which vancomycin clearance was used to determine the daptomycin dosing interval in a morbidly obese patient with renal impairment."	( Using vancomycin concentrations for dosing daptomycin in a morbidly obese patient with renal insufficiency. Allen, SE; Mercier, RC; Pai, MP, 2006)	0.33
" Daptomycin was administered empirically at 6 mg/kg dosed every 48 hours based on estimated clearance from measured vancomycin concentrations."	( Using vancomycin concentrations for dosing daptomycin in a morbidly obese patient with renal insufficiency. Allen, SE; Mercier, RC; Pai, MP, 2006)	0.33
"The dosing interval of daptomycin is adjusted based on Cl(cr)."	( Using vancomycin concentrations for dosing daptomycin in a morbidly obese patient with renal insufficiency. Allen, SE; Mercier, RC; Pai, MP, 2006)	0.33
"In this clinical scenario, vancomycin concentrations more accurately estimated Cl(cr), thereby facilitating determination of the daptomycin dosing interval."	( Using vancomycin concentrations for dosing daptomycin in a morbidly obese patient with renal insufficiency. Allen, SE; Mercier, RC; Pai, MP, 2006)	0.33
" These age-related differences in the pharmacokinetic profile of daptomycin have significant dosing implications."	( Pharmacokinetics of daptomycin in a critically ill adolescent with vancomycin-resistant enterococcal endocarditis. Akins, RL; Haase, MR; Levy, EN, 2006)	0.33
" Daptomycin was well tolerated in subjects dosed with up to 12 mg/kg intravenously for 14 days."	( Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Benvenuto, M; Benziger, DP; Vigliani, G; Yankelev, S, 2006)	0.33
" Enhancement of bactericidal activity was evaluated by calculating and comparing the areas under the bactericidal curve (AUBC) for each dosing regimen against each isolate."	( Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species. DeRyke, CA; Kuti, JL; Nicolau, DP; Sutherland, C; Zhang, B, 2006)	0.33
"Pharmacotherapy in critically ill patients receiving continuous renal replacement therapies (CRRT) is challenging due to the lack of published information to base dosing regimens."	( Daptomycin clearance during modeled continuous renal replacement therapy. Churchwell, MD; Mueller, BA; Pasko, DA, 2006)	0.33
"Dalbavancin, a semisynthetic lipoglycopeptide being developed for the treatment of skin and skin structure infections (SSSIs), has a half-life of 5 to 7 days in humans and offers promise for a convenient weekly dosing regimen."	( Bactericidal activity and resistance development profiling of dalbavancin. Draghi, DC; Goldstein, BP; Hogan, P; Sahm, DF; Sheehan, DJ, 2007)	0.34
"Given the limitations of this registry (which include its retrospective nature; limited numbers of MSSA patients; and lack of specific information on adverse events, type and duration of prior antibiotic therapy, timing and duration of concomitant antibiotic therapy, concomitant surgical interventions, and possible on-therapy dosing adjustments), daptomycin appeared effective in postmarketing clinical practice in the treatment of cSSSI caused by MRSA and MSSA."	( Efficacy of daptomycin in complicated skin and skin-structure infections due to methicillin-sensitive and -resistant Staphylococcus aureus: results from the CORE Registry. Lamp, KC; Martone, WJ, 2006)	0.33
" It has very good pharmacokinetics properties with a long half-life which allows a single intravenous daily dose and is currently approved for treatment of complicated skin and soft tissue infections at the dosage of 4 mg/kg/die and for treatment of bacteremia and endocarditis at the dosage of 6 mg/kg/die."	( [Daptomycin, the first cydal antibiotic of a new class active against Gram positive pathogens]. Esposito, S; Stefani, S, 2006)	0.33
" We attempted to determine if this occurrence was reproducible in vitro and if it could be prevented by various daptomycin dosing strategies."	( Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. Kaatz, GW; Rose, WE; Rybak, MJ, 2007)	0.34
" Bactericidal activity was noted with 6 and 10 mg/kg dosing against SA-675 with no resistance detected."	( Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. Kaatz, GW; Rose, WE; Rybak, MJ, 2007)	0.34
"The emergence of resistance was successfully recreated at suboptimal dosing regimens while the current recommended regimen of 6 mg/kg/day prevented the emergence of non-susceptible mutants."	( Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. Kaatz, GW; Rose, WE; Rybak, MJ, 2007)	0.34
"The present study characterized the single-dose pharmacokinetics of daptomycin dosed as 4 mg/kg of total body weight (TBW) in seven morbidly obese and seven age-, sex-, race-, and serum creatinine-matched healthy subjects."	( Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Anderson, T; Goade, DW; Mercier, RC; Norenberg, JP; Pai, MP; Rodvold, KA; Telepak, RA, 2007)	0.34
" It is a safe and well-tolerated antibiotic, particularly at the current dosing regimen."	( Daptomycin. Bygott, JM; Daly, ML; Enoch, DA; Karas, JA, 2007)	0.34
" The positive outcome in our patient is likely attributable to aggressive vancomycin dosing and extended duration of treatment prior to the initiation of daptomycin."	( Daptomycin use after vancomycin-induced neutropenia in a patient with left-sided endocarditis. Mergenhagen, KA; Pasko, MT, 2007)	0.34
" The pharmacokinetic and pharmacodynamic properties of daptomycin allow for once-daily dosing, although it is recommended that the dosing interval be increased to 2 days in patients with renal impairment."	( Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria. Johnson, A, 2006)	0.33
" It has rapid bactericidal activity against growing and stationary-phase bacteria, once-daily dosing regimen, and has a low potential for the development of resistance."	( Daptomycin and tigecycline: a review of clinical efficacy in the antimicrobial era. Ziglam, H, 2007)	0.34
" Daptomycin should be administered intravenously once daily, because adverse effects on skeletal muscle associated with an increase in plasma levels of creatine phosphokinase and myopathy were observed more frequently at shorter dosing intervals."	( Daptomycin: a review 4 years after first approval. Graninger, W; Joukhadar, C; Rothenburger, M; Sauermann, R, 2008)	0.35
" Historical controls received at least 3 days of vancomycin dosed to achieve trough concentrations of 5-20 microg/ml."	( Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes. Davis, SL; Delgado, G; Hall, LM; McKinnon, PS; Rose, W; Rybak, MJ; Wilson, RF, 2007)	0.34
" The patient did not respond to 5 days of appropriately dosed linezolid and daptomycin and remained bacteremic because abscess drainage was not an option in this case and the continuous, high-grade MRSA bacteremia continued despite appropriate therapy."	( Methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE) in a patient with Job's syndrome (hyperimmunoglobulin E syndrome) successfully treated with linezolid and high-dose daptomycin. Cunha, BA; Kodali, V; Krol, V, )	0.13
" Even though the infants received higher doses than adults, their drug concentrations were comparable to those observed in adults treated with regular dosing of daptomycin."	( Daptomycin use in infants: report of two cases with peak and trough drug concentrations. Benjamin, DK; Cohen-Wolkowiez, M; Fowler, VG; Smith, PB; Wade, KC, 2008)	0.35
"The need to investigate novel dosing regimens and combinations is essential in combating poor treatment outcomes for Staphylococcus aureus bacteremia and endocarditis."	( Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations. Leonard, SN; Rose, WE; Rybak, MJ, 2008)	0.35
" Moreover, these free, bioactive concentrations in tissue exceeded the MICs for staphylococci and streptococci over the 24-h dosing interval."	( In vivo microdialysis study of the penetration of daptomycin into soft tissues in diabetic versus healthy volunteers. Gao, L; Kim, A; Kuti, JL; Nicolau, DP; Suecof, LA; Sutherland, CA, 2008)	0.35
" Higher dosing at 6 mg/kg (with increased dosing interval in renal failure) should be considered in such patients as well as those at risk of bacteraemia, osteomyelitis, diabetic foot infection and in situations where there is more rapid drug clearance, such as infections complicating intravenous drug use and thermal burns."	( Daptomycin: rationale and role in the management of skin and soft tissue infections. Seaton, RA, 2008)	0.35
" Continuous vancomycin infusion in the ITU setting guarantees optimal dosing for severely ill patients."	( Are glycopeptides still appropriate and convenient for empiric use? Gonzalez-Ruiz, A; Richardson, J, 2008)	0.35
"This study demonstrated similarities between Taiwanese and Caucasian healthy subjects in the PK profiles of daptomycin, and thus the dosage regimen used in Caucasian subjects could be applied to Taiwanese."	( Pharmacokinetics and safety of multiple intravenous doses of daptomycin in a Taiwanese adult population. Chang, SC; Huang, YT; Liang, SH; Sheng, WH; Wu, FL, 2009)	0.35
" Additional studies of dosing and pharmacokinetics of intraperitoneal daptomycin in the treatment of patients with vancomycin-resistant enterococcus peritonitis are needed."	( Successful use of intraperitoneal daptomycin in the treatment of vancomycin-resistant enterococcus peritonitis. Abu-Alfa, AK; Brewster, UC; Hall, I; Huen, SC; Mahnensmith, RL; Topal, J, 2009)	0.35
"Knowledge on the elimination of antibiotics by extracorporeal hemofiltration is a prerequisite for appropriate antimicrobial dosing in patients with renal failure."	( Daptomycin elimination by CVVH in vitro: evaluation of factors influencing sieving and membrane adsorption. Steiner, I; Wagner, CC; Zeitlinger, M, 2009)	0.35
" Advantages such as superior volume control, excellent metabolic control, and hemodynamic tolerance by critically ill patients are well documented, but an understanding of drug dosing for CRRT is still a bit of a mystery."	( Drug dosing during continuous renal replacement therapy. Churchwell, MD; Mueller, BA, )	0.13
" This study determined the pharmacokinetics of intradialytically dosed daptomycin in patients with ESRD."	( Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis. Churchwell, MD; Gao, L; Heung, M; Mueller, BA; Patel, JH; Salama, NN; Segal, JH, 2009)	0.35
" The recommended dosing regimen would conflict with asymmetric thrice-weekly haemodialysis, which yields two ~44-hr and one ~68-hr interdialytic periods."	( Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients. Churchwell, MD; Gao, L; Heung, M; Mueller, BA; Patel, JH; Salama, NN; Segal, JH, 2010)	0.36
" Currently, no dosing recommendations exist for this drug for patients with acute kidney injury (AKI) undergoing renal replacement therapy."	( Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis--a pharmacokinetic study. Bode-Boeger, SM; Burkhardt, O; Eugbers, C; Hafer, C; Haller, H; Joukhadar, C; Kielstein, JT; Knitsch, W; Martens-Lobenhoffer, J; Traunmüller, F, 2010)	0.36
"3 m(2); blood and dialysate flow, 160 ml/min; ED time, 480 min) and employing current dosing regimen, 6 mg/kg daptomycin every 48 h, run the risk of becoming significantly under dosed if one adheres to a twice daily dosing schedule that is recommended for patients on maintenance haemodialysis."	( Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis--a pharmacokinetic study. Bode-Boeger, SM; Burkhardt, O; Eugbers, C; Hafer, C; Haller, H; Joukhadar, C; Kielstein, JT; Knitsch, W; Martens-Lobenhoffer, J; Traunmüller, F, 2010)	0.36
" However, daptomycin dosing and its ability to penetrate into inflamed target tissues are still a matter of controversy."	( Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. Joukhadar, C; Konz, KH; Mauric, O; Metzler, J; Popovic, M; Scharnagl, E; Schintler, MV; Spendel, S; Traunmüller, F, 2010)	0.36
" In all subjects, daptomycin was administered intravenously once daily at a dosage of 6 mg/kg body weight for 4 consecutive days at minimum."	( Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. Joukhadar, C; Konz, KH; Mauric, O; Metzler, J; Popovic, M; Scharnagl, E; Schintler, MV; Spendel, S; Traunmüller, F, 2010)	0.36
" Nearly 70% of the respondent hospitals reported having a vancomycinspecific dosing or monitoring guideline in place."	( Hospital policies and practices on prevention and treatment of infections caused by methicillin-resistant Staphylococcus aureus. Hennenfent, J; Lambert, BL; McBride, MV; Rodvold, KA; Schiff, G; Schumock, GT; Trese, AM; Tverdek, F; Yang, Y, 2010)	0.36
" The use of higher doses and less-frequent dosing of existing agents is being explored, and exciting new developments include the emergence of agents with broader-spectrum activity against drug-resistant organisms and the use of antifungal agents in the OPAT setting."	( Outpatient parenteral antimicrobial therapy: Recent developments and future prospects. Chapman, AL; Lessing, MP; Sanderson, F; Seaton, RA; Török, ME, 2010)	0.36
" Further investigation into β-lactam dosing strategies against different BORSA strains is warranted in order to avoid possible therapy failure."	( Diminished in vitro antibacterial activity of oxacillin against clinical isolates of borderline oxacillin-resistant Staphylococcus aureus. Beisser, PS; Croes, S; Deurenberg, RH; Neef, C; Stobberingh, EE; Terporten, PH, 2010)	0.36
"To investigate daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis to develop dosing recommendations."	( Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. Depestel, DD; Gao, L; Grio, M; Heung, M; Mueller, BA; Salama, NN; Sowinski, KM; Vilay, AM, 2011)	0.37
" For a successful therapy it is of vital importance that these compounds are used judiciously and dosed appropriately."	( Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. Derendorf, H; Estes, KS, 2010)	0.36
"The pharmacokinetics of daptomycin 6 mg/kg support a dosing regimen of every 48 h in CAPD and thrice-weekly dosing in HD."	( Pharmacokinetics and safety of multiple doses of daptomycin 6 mg/kg in noninfected adults undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Benziger, DP; Cannon, C; Donovan, J; Pertel, PE; Schwab, RJ; Swan, SK; Yankelev, S, 2011)	0.37
"To address issues of antibiotic dosing during sustained low-efficiency dialysis by using available pharmacokinetic data, intermittent and continuous renal replacement therapy dialysis guidelines, and our experience with sustained low-efficiency dialysis."	( Antibiotic dosing during sustained low-efficiency dialysis: special considerations in adult critically ill patients. Bogard, KN; Erwin, MW; Fuller, PD; Olsen, KM; Peterson, NT; Plumb, TJ, 2011)	0.37
"Published clinical trials, case reports, and reviews of antibiotic dosing in humans during sustained low-efficiency dialysis."	( Antibiotic dosing during sustained low-efficiency dialysis: special considerations in adult critically ill patients. Bogard, KN; Erwin, MW; Fuller, PD; Olsen, KM; Peterson, NT; Plumb, TJ, 2011)	0.37
" Appropriate dose and calculation of dosing intervals is essential to provide adequate antibiotic therapy in these patients."	( Antibiotic dosing during sustained low-efficiency dialysis: special considerations in adult critically ill patients. Bogard, KN; Erwin, MW; Fuller, PD; Olsen, KM; Peterson, NT; Plumb, TJ, 2011)	0.37
"This study identified optimal daptomycin dosing for patients receiving thrice-weekly hemodialysis (HD)."	( Use of pharmacokinetic and pharmacodynamic principles to determine optimal administration of daptomycin in patients receiving standardized thrice-weekly hemodialysis. Cardone, K; Drusano, GL; Grabe, DW; Hoy, C; Lodise, TP; Manley, H; Meola, S; Patel, N, 2011)	0.37
" Population PK modeling and Monte Carlo simulation (MCS) were used to identify CAPD dosing schemes providing efficacy and toxicity plasma profiles comparable with those obtained from MCS using the daptomycin population PK model derived from patients in the Staphylococcus aureus bacteremia-infective endocarditis (SAB-IE) study."	( Pharmacokinetics and pharmacodynamics of intravenous daptomycin during continuous ambulatory peritoneal dialysis. Cardone, KE; Drusano, GL; Grabe, DW; Hoy, CD; Lodise, TP; Manley, HJ; Meola, S; Patel, N, 2011)	0.37
" daptomycin 4 or 6 mg/kg, depending on indication, every 48 h was identified as the optimal CAPD dosing scheme."	( Pharmacokinetics and pharmacodynamics of intravenous daptomycin during continuous ambulatory peritoneal dialysis. Cardone, KE; Drusano, GL; Grabe, DW; Hoy, CD; Lodise, TP; Manley, HJ; Meola, S; Patel, N, 2011)	0.37
" CAPD dosing scheme."	( Pharmacokinetics and pharmacodynamics of intravenous daptomycin during continuous ambulatory peritoneal dialysis. Cardone, KE; Drusano, GL; Grabe, DW; Hoy, CD; Lodise, TP; Manley, HJ; Meola, S; Patel, N, 2011)	0.37
" Overall, most indications and dosing regimens of daptomycin were within the health authorities' approved criteria, although the antibiotic was sometimes used for other clinical situations and at doses higher than those currently established."	( [Clinical experience with daptomycin use in Spain. Global findings from EU-CORE database]. Almirante, B, 2010)	0.36
" The recommended dosage in patients with previous renal impairment is 4 mg/kg/48 hours in SSTI."	( [Safety of daptomycin in patients with renal impairment]. Azanza, JR; Quetglas, EG, 2010)	0.36
" Currently, the daptomycin dosage is 4 mg/kg/day for treatment of complicated skin and soft-tissue infections and 6 mg/kg/day for Staphylococcus aureus bloodstream infections, including those with right-sided endocarditis, however higher doses (>6 mg/kg/day) have been explored as a possible alternative."	( Daptomycin: evaluation of a high-dose treatment strategy. Abraham, T; Balmir, E; Rapp, J; Saad, N; Vastey, F; Wu, G, 2011)	0.37
"To determine the safety of daptomycin administered using a variety of doses and dosing frequencies in patients receiving intermittent hemodialysis who had probable or confirmed gram-positive infections."	( Safety of daptomycin in patients receiving hemodialysis. Crompton, JA; Donovan, BJ; Lamp, KC; Mueller, BA; Yankalev, S, 2011)	0.37
" Of the 393 patients, 370 (94%) could be categorized by daptomycin dosing frequency: every 48 hours (251 patients [64%]), 3 times/week (87 [22%]), and every 24 hours (32 [8%]); the remaining 23 (6%) had unreported dosing frequencies or received a single dose of daptomycin."	( Safety of daptomycin in patients receiving hemodialysis. Crompton, JA; Donovan, BJ; Lamp, KC; Mueller, BA; Yankalev, S, 2011)	0.37
"In these patients undergoing hemodialysis, daptomycin was a well-tolerated treatment for gram-positive infections across several doses and dosing frequencies."	( Safety of daptomycin in patients receiving hemodialysis. Crompton, JA; Donovan, BJ; Lamp, KC; Mueller, BA; Yankalev, S, 2011)	0.37
"The dosing regimen of 4 mg/kg TBW of daptomycin administered to CVVHD patients every 48 h is inappropriate to achieve effective antimicrobial plasma concentrations of daptomycin in the second half of the dosing interval (24 - 48 h)."	( Plasma pharmacokinetics of daptomycin in critically ill patients with renal failure and undergoing CVVHD. Eggers, K; Joukhadar, C; Khadzhynov, D; König, T; Lieker, I; Neumayer, HH; Peters, H; Puhlmann, B; Slowinski, T; Spies, C; Traunmüller, F; Uhrig, A, 2011)	0.37
" This study was performed to develop dosing recommendations in continuous venovenous haemodiaﬁltration (CVVHDF)."	( Multiple-dose pharmacokinetics of daptomycin during continuous venovenous haemodiafiltration. Dittrich, P; Fuhrmann, V; Meyer, B; Saria, K; Thalhammer, F; Wenisch, JM; Zuba, C, 2012)	0.38
"Limited data are available on the pharmacokinetics and optimal dosage of daptomycin, a lipopeptide compound possessing activity against Gram-positive bacteria, in the pediatric population, particularly in neonates and infants."	( Serum levels of daptomycin in pediatric patients. Antachopoulos, C; Bazoti, F; Drossou-Agakidou, V; Gikas, E; Iosifidis, E; Katragkou, A; Roilides, E; Sarafidis, K, 2012)	0.38
" A dosage of 6 mg/kg/12 h of daptomycin to the infants resulted in trough concentrations of <4-8."	( Serum levels of daptomycin in pediatric patients. Antachopoulos, C; Bazoti, F; Drossou-Agakidou, V; Gikas, E; Iosifidis, E; Katragkou, A; Roilides, E; Sarafidis, K, 2012)	0.38
"A dosage of daptomycin 6 mg/kg/12 h in small infants results in lower peak and similar trough concentrations compared with a dosage of 4 mg/kg/day administered to adults."	( Serum levels of daptomycin in pediatric patients. Antachopoulos, C; Bazoti, F; Drossou-Agakidou, V; Gikas, E; Iosifidis, E; Katragkou, A; Roilides, E; Sarafidis, K, 2012)	0.38
" In this mouse model of surgical implant MSSA or MRSA infection, daptomycin and tigecycline prophylaxis were effective over a broader dosage range than vancomycin."	( Daptomycin and tigecycline have broader effective dose ranges than vancomycin as prophylaxis against a Staphylococcus aureus surgical implant infection in mice. Billi, F; Francis, KP; Miller, LS; Niska, JA; Pribaz, JR; Ramos, RI; Shahbazian, JH, 2012)	0.38
" Pharmacokinetic studies and data from the CORE Registry have allowed improved the dosing regimen in patients under hemodialysis, peritoneal dialysis and other extrarenal depuration techniques."	( [Daptomycin in the treatment of Gram-positive infections in patients with chronic renal failure]. Sarriá Cepeda, C, 2012)	0.38
"The impact of an institutional protocol intended to improve daptomycin dosing for vancomycin-resistant enterococci (VRE) infections was investigated."	( Evaluation of a daptomycin dose-optimization protocol. Cottreau, J; Garey, KW; Hirsch, EB; Palmer, HR; Shah, DN; Tam, VH; Tran, TT; Weston, J, 2012)	0.38
" As part of an initiative to optimize daptomycin dosing for all indications and regimens, a large medical center implemented a protocol restricting daptomycin prescribing to infectious-diseases specialists and a nomogram recommending elevated daptomycin dosing for all VRE infections, with baseline and weekly creatinine phosphokinase (CPK) determinations during daptomycin therapy."	( Evaluation of a daptomycin dose-optimization protocol. Cottreau, J; Garey, KW; Hirsch, EB; Palmer, HR; Shah, DN; Tam, VH; Tran, TT; Weston, J, 2012)	0.38
"Implementation of a daptomycin dosing protocol by a multidisciplinary antimicrobial stewardship team optimized treatment by increasing the mean dose of daptomycin administered to hospitalized adults with non-urinary VRE infections and improved the rate of safety monitoring."	( Evaluation of a daptomycin dose-optimization protocol. Cottreau, J; Garey, KW; Hirsch, EB; Palmer, HR; Shah, DN; Tam, VH; Tran, TT; Weston, J, 2012)	0.38
"For critically ill patients undergoing continuous renal replacement therapy (CRRT), daptomycin dosing recommendations are scarce."	( Experience with daptomycin daily dosing in ICU patients undergoing continuous renal replacement therapy. Corti, N; Fehr, J; Preiswerk, B; Rudiger, A, 2013)	0.39
" Peak and trough concentrations showed a high intra- and inter-patient variability in both groups, independent of the dosage per kg body weight."	( Experience with daptomycin daily dosing in ICU patients undergoing continuous renal replacement therapy. Corti, N; Fehr, J; Preiswerk, B; Rudiger, A, 2013)	0.39
"In critically ill patients undergoing CRRT, daptomycin exposure with once-daily dosing was similar to ICU patients with normal renal function, but lower compared to healthy volunteers."	( Experience with daptomycin daily dosing in ICU patients undergoing continuous renal replacement therapy. Corti, N; Fehr, J; Preiswerk, B; Rudiger, A, 2013)	0.39
" The aggressive vancomycin dosing regimens are still associated with unacceptable high microbiological failure rates and it is not currently possible to achieve probability of target attainment at higher vancomycin MICs of 2 mg/l."	( Does resistance in severe infections caused by methicillin-resistant Staphylococcus aureus give you the 'creeps'? Brink, AJ, 2012)	0.38
"Continued monitoring of patients on aggressive vancomycin dosing schedules is advised."	( Does resistance in severe infections caused by methicillin-resistant Staphylococcus aureus give you the 'creeps'? Brink, AJ, 2012)	0.38
"While the pharmacokinetic (PK) properties of daptomycin in hemodialysis (HD) patients have been evaluated previously by three groups, resultant dosing recommendations have varied."	( Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis. Butterfield, JM; Cardone, KE; Grabe, DW; Lodise, TP; Mueller, BA; Patel, N; Salama, NN, 2013)	0.39
" Dose-response data were analyzed by a maximum effect (E(max)) model using nonlinear regression."	( Inoculum effects of ceftobiprole, daptomycin, linezolid, and vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at inocula of 10(5) and 10(7) CFU injected into opposite thighs of neutropenic mice. Andes, DR; Craig, WA; Lee, DG; Murakami, Y, 2013)	0.39
" Patients receiving a daptomycin dosage of 8 mg/kg/day had significantly higher values of mean C max and AUC0-24."	( Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary? Cassetta, MI; d'Ettorre, G; Falcone, M; Fallani, S; Lappa, A; Novelli, A; Russo, A; Tritapepe, L; Venditti, M, 2013)	0.39
"Increasing the dosage of daptomycin may be advantageous in severe infection by enhancing bactericidal activity and pharmacodynamics."	( Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patients. Chang, SC; Chen, YC; Cheng, A; Chuang, YC; Lai, CC; Sheng, WH; Wang, JT, 2013)	0.39
" A combination of daptomycin plus trimethoprim/sulfamethoxazole (TMP/SMX) was administered for six weeks, followed by a high dosage of TMP/SMX for a further six weeks."	( High dose of trimethoprim-sulfamethoxazole and daptomycin as a therapeutic option for MRSA endocarditis with large vegetation complicated by embolic stroke: a case report and literature review. Bonura, C; D'Alessandro, N; Di Carlo, P; Giarratano, A; Guadagnino, G; Lunetta, M; Mammina, C; Novo, S, 2013)	0.39
" aureus (VSSA) JKD6009 to simulated human vancomycin dosing regimens (500 mg to 4,000 mg every 12 h) using a 10-day hollow fiber infection model."	( Decreased vancomycin susceptibility in Staphylococcus aureus caused by IS256 tempering of WalKR expression. Doig, K; Gao, W; Howden, BP; McEvoy, CR; Ngo, D; Porter, JL; Seemann, T; Stinear, TP; Tsuji, B, 2013)	0.39
"A total of 126 hospitalized adult obese patients (body mass index [BMI] more than 30 kg/m(2) ) admitted from January 2005 through May 2010 who received daptomycin dosed on actual body weight for any indication for a minimum of 7 days."	( Safety and effectiveness of daptomycin across a hospitalized obese population: results of a multicenter investigation in the southeastern United States. Bland, CM; Bookstaver, PB; Caulder, CR; Faulkner-Fennell, CM; Hartis, C; Qureshi, ZP; Sheldon, MA, 2013)	0.39
" Daptomycin was generally administered at a planned dosage regimen of ≥ 5 mg/kg every 24 hours in patients with normal to moderately impaired kidney function or every 48 hours in patients with severe kidney disease."	( Use of daptomycin in the treatment of vancomycin-resistant enterococcal urinary tract infections: a short case series. Amodio-Groton, M; Ramaswamy, DP; Scholand, SJ, 2013)	0.39
"We describe the case of an intravenous drug user affected by life-threatening Staphylococcus aureus-complicated skin and soft tissue infection with associated bacteraemia who, while on replacement therapy with methadone, required 11 mg/kg/day daptomycin to achieve trough (Cmin) and peak (Cmax) plasma levels similar to those observed with the standard dosage of 6 mg/kg in healthy volunteers (mean ± standard deviation: Cmin 12."	( Daptomycin underexposure in a young intravenous drug user who was affected by life-threatening Staphylococcus aureus-complicated skin and soft tissue infection associated with bacteraemia. Bassetti, M; Cojutti, P; Crapis, M; Pea, F, 2014)	0.4
"To support daptomycin dosing recommendations in patients with Staphylococcus aureus bacteraemia (SAB) and severe renal impairment using simulations from a population pharmacokinetic model for daptomycin."	( Clinical and pharmacokinetic considerations for the use of daptomycin in patients with Staphylococcus aureus bacteraemia and severe renal impairment. Benziger, D; Chakraborty, A; Chaves, RL; Tannenbaum, S, 2014)	0.4
" Daptomycin 24 h AUC and Cmax were then simulated for subjects with a CL(CR) < 30 mL/min [with or without haemodialysis (HD) or continuous ambulatory peritoneal dialysis (CAPD)] for different dosing frequencies (every 24 h, every 48 h and three times weekly) with doses of 4 mg/kg and 6 mg/kg."	( Clinical and pharmacokinetic considerations for the use of daptomycin in patients with Staphylococcus aureus bacteraemia and severe renal impairment. Benziger, D; Chakraborty, A; Chaves, RL; Tannenbaum, S, 2014)	0.4
" Daptomycin concentrations were measured intensively over the initial 96-hour dosing period."	( Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Falcone, M; Novelli, A; Pai, MP; Russo, A; Venditti, M, 2013)	0.39
"A reappraisal of current daptomycin dosing recommendations is needed to improve the PTA and reduce toxicity among critically ill patients."	( Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Falcone, M; Novelli, A; Pai, MP; Russo, A; Venditti, M, 2013)	0.39
"The optimal daptomycin dosing regimen for critically ill patients undergoing continuous renal replacement therapy (CRRT) has still to be established."	( Pharmacokinetics of daily daptomycin in critically ill patients undergoing continuous renal replacement therapy. Béchir, M; Chiesa, A; Corti, N; Jetter, A; Maggiorini, M; Marti, I; Müller, D; Rentsch, K; Rudiger, A, 2013)	0.39
"Daptomycin use at our institution changed to ideal body weight dosing based on a published analysis of pharmacokinetic-pharmacodynamic efficacy target attainment, bacterial ecology, and a desire to reduce drug toxicity."	( Daptomycin dosing based on ideal body weight versus actual body weight: comparison of clinical outcomes. Andes, DR; Buhr, KA; Fish, JT; Fox, BC; Ng, JK; Rose, WE; Schulz, LT, 2014)	0.4
"To determine the optimal dosing regimen of daptomycin in patients receiving thrice-weekly hemodialysis."	( Daptomycin dosing strategies in patients receiving thrice-weekly intermittent hemodialysis. Bohm, N; Haselden, M; Leach, M, 2013)	0.39
" However, the daptomycin prescribing information recommends dosing every 48 hours in patients receiving hemodialysis, which results in dyssynchrony of dosing and dialysis sessions every other week."	( Daptomycin dosing strategies in patients receiving thrice-weekly intermittent hemodialysis. Bohm, N; Haselden, M; Leach, M, 2013)	0.39
" Discontinuation of therapy because of elevated CPK levels may have been avoided in some patients with adjustment to every 48-hour dosing for Clcr less than 30 ml/minute."	( Efficacy and safety of daptomycin in patients with renal impairment: a multicenter retrospective analysis. Geriak, M; Kullar, R; McClellan, I; Sakoulas, G, 2014)	0.4
"5 h and 3 h and Ct in 15-min increments within an hour of the end of the dosing interval for each dose."	( Simplified equations using two concentrations to calculate area under the curve for antimicrobials with concentration-dependent pharmacodynamics: daptomycin as a motivating example. Falcone, M; Novelli, A; Pai, MP; Russo, A; Venditti, M, 2014)	0.4
"A case series in which a novel dosing strategy for managing mild, asymptomatic creatine kinase (CK) increases associated with daptomycin therapy is presented."	( Dosing strategy to allow continued therapy with daptomycin after asymptomatic increases in creatine kinase levels. Benziger, D; Burdette, SD; McDaneld, PM; Oleson, F; Patel, HN, 2014)	0.4
"Daptomycin is used off-label for enterococcal infections; however, dosing targets for resistance prevention remain undefined."	( Defining daptomycin resistance prevention exposures in vancomycin-resistant Enterococcus faecium and E. faecalis. Arias, CA; Ireland, CE; Murray, BE; Nonejuie, P; Pogliano, J; Rose, WE; Rybak, MJ; Sakoulas, G; Steed, ME; Tran, TT; Werth, BJ, 2014)	0.4
" We planned for rapid load and CSF sterilization and extended the dosing interval once drug accumulation was expected to have occurred."	( Successful treatment of ventriculostomy-associated meningitis caused by multidrug resistant coagulase-negative Staphylococcus epidermidis using low-volume intrathecal daptomycin and loading strategy. Denetclaw, TH; Suehiro, I; Tolliver, GL; Wang, PK, 2014)	0.4
"IT daptomycin 5 mg diluted to 3 mL in NS and dosed in a loading strategy was effective and without adverse sequelae."	( Successful treatment of ventriculostomy-associated meningitis caused by multidrug resistant coagulase-negative Staphylococcus epidermidis using low-volume intrathecal daptomycin and loading strategy. Denetclaw, TH; Suehiro, I; Tolliver, GL; Wang, PK, 2014)	0.4
" The main objective of this review is to compare the relative efficacies, dosing strategies, and side-effect profiles of quinupristin-dalfopristin, linezolid, and daptomycin for VRE bacteremia in the pediatric population."	( Optimizing therapy for vancomycin-resistant enterococcal bacteremia in children. Hsu, AJ; Tamma, PD, 2014)	0.4
" Daptomycin exposures based on mg/kg dosing were lower than previously reported for older children and adults, likely because of increased clearance and volume of distribution and decreased apparent elimination half-life."	( Single-dose pharmacokinetics of daptomycin in pediatric patients 3-24 months of age. Benziger, D; Bokesch, P; Bradley, JS; Jacobs, R, 2014)	0.4
" The data collected in adults can only be transferred to children older than 12 years, and the information available is not sufficient to determine the dosage that will assure the highest antimicrobial efficacy with only marginal risks of adverse events in younger patients."	( Daptomycin in paediatrics: current knowledge and the need for future research. Caironi, M; Esposito, S; Pani, L; Principi, N; Venturini, F, 2015)	0.42
" With a further dosage reduction and continued administration of sodium polystyrene sulfonate, the patient completed the full course of daptomycin therapy."	( Daptomycin-induced hyperkalemia in a patient with normal renal function. Berger, B; Blum, S; Budovich, A, 2014)	0.4
" Finally, we examined the ability of pulse dosing an antibiotic to eliminate persisters."	( Borrelia burgdorferi, the Causative Agent of Lyme Disease, Forms Drug-Tolerant Persister Cells. Brown, AV; Hu, LT; Lewis, K; Matluck, NE; Sharma, B, 2015)	0.42
" In conclusion, no clear correlation between PK/PD indices and the probability of efficacy or safety events was demonstrated when daptomycin was administered in SSTI patients using the clinically recommended dosage of 4 mg/kg/day."	( Correlation between pharmacokinetic/pharmacodynamic indices and clinical outcomes in Japanese patients with skin and soft tissue infections treated with daptomycin: analysis of a phase III study. Aikawa, N; Ishii, M; Kusachi, S; Mikamo, H; Takahashi, K; Takesue, Y; Watanabe, S; Yoshinari, T, 2015)	0.42
"We aimed to characterize real-world dosing of weight-based intravenous (IV) antibiotic therapy in patients hospitalized for methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft-tissue infections (cSSTIs)."	( Weight-based antibiotic dosing in a real-world European study of complicated skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus. Baillon-Plot, N; Charbonneau, C; Corman, S; Eckmann, C; Haider, S; Lawson, W; Li, J; Macahilig, C; Nathwani, D; Solem, C; Stephens, J, 2015)	0.42
"We report our clinical experience with the use of daptomycin, administered in the dosage of 8 mg/kg/d in 3 minutes, in treating 12 critically ill children younger than 12 years, with bloodstream infections (n = 9) and complicated skin and soft-tissue infections (n = 3)."	( Use of Daptomycin in Critically Ill Children With Bloodstream Infections and Complicated Skin and Soft-tissue Infections. Conti, M; Giannella, M; Tedeschi, S; Tumietto, F; Viale, P, 2016)	0.43
" Considering the analysis of daptomycin in a pharmaceutical dosage form, the only method found in literature uses potentially toxic organic solvents."	( Development, Optimization, and Validation of a Green and Stability-Indicating HPLC Method for Determination of Daptomycin in Lyophilized Powder. Salgado, HR; Tótoli, EG, )	0.13
" Daptomycin, as first-line therapy for the treatment of severe MRSA infections, should be used at optimal dosage combined with other agents such as beta-lactams, to prevent daptomycin resistance occurrence."	( In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant Staphylococcus aureus severe infections previously treated with glycopeptides. Cafiso, V; Campanile, F; Capone, A; Mariani, B; Parisi, G; Petrosillo, N; Stefani, S, 2016)	0.43
" The mean dosage was 9 mg/kg/day (5-11 mg/kg/day) for a mean duration of 11 days (2; 55 days)."	( Study on daptomycin use and implementation of an antimicrobial stewardship program. Castel, C; Cattoir, V; de La Blanchardière, A; Michon, J; Saint-Lorant, G, 2016)	0.43
"Faced with a lack of recent recommendations on the subject, our multidisciplinary team issued a local consensus, defining the indications and dosage modalities for this reserve antibiotic."	( Study on daptomycin use and implementation of an antimicrobial stewardship program. Castel, C; Cattoir, V; de La Blanchardière, A; Michon, J; Saint-Lorant, G, 2016)	0.43
" She had acute kidney injury, requiring daptomycin dosage adjustment."	( Successful Use of High-dose Daptomycin in a Child With Staphylococcus aureus Endocarditis. Gnanasambandam, S; Kanjani, A; Nambi, PS; Prabhudesai, S; Ramachandran, B, 2016)	0.43
" Appropriate antibiotic selection and adequate dosing are important for improving patient outcomes."	( Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients. Baietto, L; D'Avolio, A; De Rosa, FG; Di Perri, G; Pacini, G; Pensi, D, 2016)	0.43
"Implementation of a standardized daptomycin dosing protocol in a community teaching hospital to determine potential cost savings, effectiveness, and safety is presented."	( Evaluation of a standardized daptomycin dosing nomogram. Maxwell, A; Schmidt, S; Sloan, A; Swindler, J, 2016)	0.43
"Implementation of a standardized dosing nomogram reduced the amount of daptomycin wasted and resulted in cost savings."	( Evaluation of a standardized daptomycin dosing nomogram. Maxwell, A; Schmidt, S; Sloan, A; Swindler, J, 2016)	0.43
"5 mg/L when using a dosage from 4 to 12 mg/kg."	( Mutant prevention concentrations of daptomycin for Enterococcus faecium clinical isolates. Auzou, M; Cattoir, V; Giard, JC; Jaussaud, C; Sinel, C, 2016)	0.43
"The objective of this population pharmacokinetic (PK) analysis was to provide guidance for the dosing interval of daptomycin in patients undergoing continuous renal replacement therapy (CRRT)."	( Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapy. Chaves, RL; Corti, N; Hamed, K; Khadzhynov, D; Levi, M; Peters, H; Xu, X, 2017)	0.46
" One of two groups comprised patients received the loading dose of daptomycin on day 1 (group 1) and the other group received normal dosage (4-6 mg/kg/day) (group 2)."	( Clinical effectiveness of daptomycin loading dose in patients infected with Gram-positive pathogens. Hagihara, M; Kato, H; Koizumi, Y; Matsuura, K; Mikamo, H; Nishiyama, N; Yamagishi, Y, 2017)	0.46
" Daptomycin was administered once daily with dosing by patient age: 12 to 17 years, 5 mg/kg; 7 to 11 years, 7 mg/kg; 2 to 6 years, 9 mg/kg; 12 to 23 months, 10 mg/kg."	( Daptomycin for Complicated Skin Infections: A Randomized Trial. Anastasiou, D; Arnold, SR; Arrieta, A; Bokesch, P; Bradley, J; Congeni, B; Daum, RS; Glasser, C; Kojaoghlanian, T; Patino, H; Wolf, DJ; Yoon, M, 2017)	0.46
"73 m 2 and Alb 15-25 g/L, suboptimal PTAs (<60%) were predicted even with 12 mg/kg/day dosing ."	( Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies. Candoni, A; Cojutti, PG; Fanin, R; Hope, W; Lazzarotto, D; Pea, F; Ramos-Martin, V; Zannier, ME, 2017)	0.46
" Daptomycin was dosed once daily by patient age: 12-17 years, 7 mg/kg; 7-11 years, 9 mg/kg and 1-6 years, 12 mg/kg."	( Randomized Multicenter Study Comparing Safety and Efficacy of Daptomycin Versus Standard-of-care in Pediatric Patients With Staphylococcal Bacteremia. Arrieta, AC; Bensaci, M; Bokesch, P; Bradley, JS; Du, L; Glasser, C; Grandhi, A; Kartsonis, NA; Patino, H; Popejoy, MW, 2018)	0.48
" Recent literature suggests that daptomycin, a cyclic lipopeptide antibiotic with concentration-dependent bactericidal activity, is the preferred treatment option for VRE bacteraemia, yet the optimal dosing strategy for this indication has not been established."	( Association of daptomycin dosing regimen and mortality in patients with VRE bacteraemia: a review. Aitken, SL; Arias, CA; Foolad, F; Shelburne, SA; Taylor, BD, 2018)	0.48
" No adverse events were observed, but the toxicity of the 10 mg/kg q24h dosing regimen should be further assessed, particularly for patients with altered renal function."	( Population pharmacokinetics of daptomycin in critically ill patients with various degrees of renal impairment. Asehnoune, K; Barbaz, M; Couet, W; Ferrandière, M; Gaillard, T; Grégoire, N; Lasocki, S; Launey, Y; Marchand, S; Mimoz, O; Seguin, P; Vourc'h, M, 2019)	0.51
" Simulations performed with the model showed that sex and P-gp haplotype may influence the PTA for high MIC values and that a dosage of 10 mg/kg/24 h would optimize efficacy."	( Genetic polymorphisms of ABCB1 (P-glycoprotein) as a covariate influencing daptomycin pharmacokinetics: a population analysis in patients with bone and joint infection. Becker, A; Bricca, R; Chidiac, C; Conrad, A; Ferry, T; Gagnieu, MC; Goutelle, S; Laurent, F; Roux, S; Triffault-Fillit, C; Valour, F, 2019)	0.51
" Gender and P-gp gene polymorphism should be further examined as determinants of dosage requirements."	( Genetic polymorphisms of ABCB1 (P-glycoprotein) as a covariate influencing daptomycin pharmacokinetics: a population analysis in patients with bone and joint infection. Becker, A; Bricca, R; Chidiac, C; Conrad, A; Ferry, T; Gagnieu, MC; Goutelle, S; Laurent, F; Roux, S; Triffault-Fillit, C; Valour, F, 2019)	0.51
"The objective of this study was to explore the optimal dosage regimen of daptomycin and to determine the necessity and validity of a high-dose regimen from the perspectives of PK/PD parameters using Monte Carlo Simulation (MCS) and therapeutic drug monitoring (TDM) in a Japanese clinical setting."	( Clinical pharmacokinetic and pharmacodynamic analysis of daptomycin and the necessity of high-dose regimen in Japanese adult patients. Aoki, Y; Hamada, Y; Magarifuchi, H; Oka, Y; Okinaka, T; Urakami, T; Yamakuchi, H, 2019)	0.51
" At an initially recommended dosage of 6mg/kg, bone concentrations are likely to be effective against staphylococcal infections and infections due to low-MIC Enterococcus."	( Bone penetration of daptomycin in diabetic patients with bacterial foot infections. Argemi, X; Boeri, C; Gaudias, J; Grillon, A; Hansmann, Y; Jehl, F; Jenny, JY; Lefebvre, N; Ronde-Ousteau, C, 2019)	0.51
" The side-effects of Daptomycin dosage through intravenous administration have prompted the experimental use of topical Daptomycin."	( Oligodynamic Boons of Daptomycin and Noble Metal Nanoparticles Packaged in an Anti-MRSA Topical Gel Formulation. Chakravarty, I; Kundu, S, 2019)	0.51
" faecium, a susceptible dose-dependent (SDD) breakpoint of ≤4 μg/mL was established based on an increased dosage of 8-12 mg/kg/day (≥8 μg/mL-resistant)."	( Development of Daptomycin Susceptibility Breakpoints for Enterococcus faecium and Revision of the Breakpoints for Other Enterococcal Species by the Clinical and Laboratory Standards Institute. Campeau, SA; Humphries, RM; Jorgensen, JH; Kuti, JL; Lewis Ii, JS; Nicolau, DP; Satlin, MJ; Weinstein, MP, 2020)	0.56
"In order to improve the stability of AgNPs and decrease the dosage of Daptomycin for killing bacteria, a reduced graphene oxide (rGO) was used for simultaneously anchoring AgNPs and Daptomycin to prepare rGO@Ag@Dap nanocomposites."	( Daptomycin and AgNP co-loaded rGO nanocomposites for specific treatment of Gram-positive bacterial infection in vitro and in vivo. Fan, J; Li, L; Liu, B; Liu, X; Tong, C; Wu, Z; Xiao, F; Zhong, X; Zhou, J, 2019)	0.51
"The objective of this study was to evaluate the efficacy of various daptomycin dosing regimens against Staphylococcus aureus and Enterococcus faecium in pediatric patients with proven/suspected gram-positive infection."	( Pharmacokinetic/Pharmacodynamic Analysis of Daptomycin Against Staphylococcus aureus and Enterococcus faecium in Pediatric Patients by Monte Carlo Simulation. Li, X; Wei, XC; Xiao, X; Zhao, MF, 2020)	0.56
"The dosing regimen of daptomycin for critically ill patients undergoing continuous renal replacement therapy (CRRT) remains controversial."	( Population pharmacokinetics and dosing considerations of daptomycin in critically ill patients undergoing continuous renal replacement therapy. Cheng, Z; Li, S; Xie, F, 2020)	0.56
" Efficacy analysis demonstrated that q48h dosing is associated with an extremely low probability of bactericidal target attainment on every second day after dosing and q24h dosing is preferred for a high probability of bactericidal target attainment."	( Population pharmacokinetics and dosing considerations of daptomycin in critically ill patients undergoing continuous renal replacement therapy. Cheng, Z; Li, S; Xie, F, 2020)	0.56
" Technical factors included investment in the optimization of dosing for improved drug exposure, toxicological evaluation of the purified eutomer from a diastereomer and the failure to develop an effective research formulation."	( Decision making in the pharmaceutical industry - A tale of three antibiotics. Hunt, A; Kirsch, DR, 2020)	0.56
" Its elimination is mainly renal, with about 50% of the dose excreted unchanged in the urine, justifying dosage adjustment for patients with renal insufficiency."	( Clinical Pharmacokinetics of Daptomycin. Buyck, J; Chauzy, A; Couet, W; Gregoire, N; Marchand, S; Rammaert, B, 2021)	0.62
"Daptomycin is increasingly used in the treatment of bone and joint infection (BJI), but its pharmacokinetics (PK) and dosage requirements have not been thoroughly investigated in this indication."	( Population pharmacokinetics of daptomycin in patients with bone and joint infection: minimal effect of rifampicin co-administration and confirmation of a sex difference. Bourguignon, L; Bricca, R; Conrad, A; Ferry, T; Gagnieu, MC; Garreau, R; Goutelle, S; Roux, S, 2021)	0.62
"To investigate the population PK and dosage requirements of daptomycin in patients with BJI, and examine the influence of rifampicin co-administration."	( Population pharmacokinetics of daptomycin in patients with bone and joint infection: minimal effect of rifampicin co-administration and confirmation of a sex difference. Bourguignon, L; Bricca, R; Conrad, A; Ferry, T; Gagnieu, MC; Garreau, R; Goutelle, S; Roux, S, 2021)	0.62
"A daptomycin dosage of 8 mg/kg/24 h in women and 10 mg/kg/24 h in men should optimize efficacy but may lead to excessive trough concentrations in many patients, especially in women."	( Population pharmacokinetics of daptomycin in patients with bone and joint infection: minimal effect of rifampicin co-administration and confirmation of a sex difference. Bourguignon, L; Bricca, R; Conrad, A; Ferry, T; Gagnieu, MC; Garreau, R; Goutelle, S; Roux, S, 2021)	0.62
" Our results suggest that in clinical use of the tested antibiotics during CRRT with the ATA hemofilter, the same factors have to be considered for determining the dosing strategy as with filters with other commonly applied membrane materials."	( Antibiotics Removal by Continuous Venovenous Hemofiltration with a Novel Asymmetric Triacetate Membrane Hemofilter: An in vitro Study. Heskamp, B; Körtge, A; Majcher-Peszynska, J; Mitzner, S; Wasserkort, R, 2021)	0.62
" To optimize vancomycin activity, dosage was adjusted to achieve an AUC/MIC ≥400."	( Effectiveness of vancomycin plus cloxacillin compared with vancomycin, cloxacillin and daptomycin single therapies in the treatment of methicillin-resistant and methicillin-susceptible Staphylococcus aureus in a rabbit model of experimental endocarditis. Almela, M; Cañas-Pacheco, MA; Castañeda, X; Dahl, A; Falces, C; Fuster, D; García-De-la-Mària, C; García-González, J; Gasch, O; Hernández-Meneses, M; Llopis, J; Marco, F; Miró, JM; Moreno, A; Pericàs, JM; Quintana, E; Soy, D; Tolosana, JM; Vidal, B, 2021)	0.62
"The objective of this systematic review is to evaluate dosing regimens of combination salvage regimens used as part of infectious disease pharmacotherapy."	( Dosing Considerations for Combination Antistaphylococcal β-Lactam and Glyco/lipopeptide Salvage Therapy for Resistant Gram-Positive Infections: A Systematic Review. Brown, M; Ofori, R; Reinert, JP, 2022)	0.72
" This work describes the heterogeneity of dosing regimens and seeks to define an optimal dose, duration, and combination of antibiotics."	( Dosing Considerations for Combination Antistaphylococcal β-Lactam and Glyco/lipopeptide Salvage Therapy for Resistant Gram-Positive Infections: A Systematic Review. Brown, M; Ofori, R; Reinert, JP, 2022)	0.72
" Relative to 24 h controls, a dose-response in bacterial killing (range -0."	( Efficacy assessment of lysin CF-296 in addition to daptomycin or vancomycin against Staphylococcus aureus in the murine thigh infection model. Asempa, TE; Cassino, C; DeRosa, NA; Lehoux, D; Nicolau, DP; Schuch, R, 2021)	0.62
" It also highlights the need for more research to identify optimal antimicrobial dosing strategies in similar scenarios."	( A successful daptomycin and micafungin dosing strategy in veno-venous ECMO and continuous renal replacement. Cabanilla, MG; Villalobos, N, 2022)	0.72
" Twelve patients received daptomycin, and dosing information was recovered for 10."	( Daptomycin susceptibility testing and therapeutic use in enterococcal bloodstream infection (EBSI) in a setting with high rates of vancomycin-resistant Enterococcus faecium (VREfm). Dewar, S; Kelly, J; Tysall, L, 2022)	0.72
"Use of daptomycin at doses ≥ 6 mg/kg for treatment of osteomyelitis is increasing in clinical practice; unfortunately, limited data are available to guide optimal dosing and duration."	( Patterns of Care and Treatment Outcomes for Outpatient Daptomycin-Containing Regimens in Osteomyelitis. Delate, T; Haghigatgoo, A; Nguyen, JK; Niu, F; Truong, JT, 2021)	0.62
" Current guidelines recommend higher daptomycin doses (8-10 mg/kg) for severe infections; however, pharmacokinetic (PK) and pharmacodynamic-based dosing strategies are still limited."	( Simplified daptomycin dosing regimen for adult patients with methicillin-resistant Staphylococcus aureus infections based on population pharmacokinetic analysis. Egashira, N; Ieiri, I; Kitaichi, K; Maeshiro, Y; Miyake, N; Nishida, R; Oida, Y; Shimono, N; Soda, M; Yamada, T; Yamashita, Y, 2022)	0.72
" Previous work showed that the approved dosage of daptomycin may be insufficient to achieve optimal exposure in patients with bone and joint infection."	( Daptomycin Physiology-Based Pharmacokinetic Modeling to Predict Drug Exposure and Pharmacodynamics in Skin and Bone Tissues. Bourguignon, L; Ferry, T; Garreau, R; Goutelle, S; Grillon, A; Jehl, F; Montange, D, 2022)	0.72
" Results of dosing simulations showed that doses ≥10 mg/kg should be used in the case of bacteremia caused by Staphylococcus aureus with a minimum inhibitory concentration >0."	( Daptomycin Physiology-Based Pharmacokinetic Modeling to Predict Drug Exposure and Pharmacodynamics in Skin and Bone Tissues. Bourguignon, L; Ferry, T; Garreau, R; Goutelle, S; Grillon, A; Jehl, F; Montange, D, 2022)	0.72
"We developed the first daptomycin PBPK/pharmacodynamic model for bone and joint infection, which confirmed that a higher daptomycin dosage is needed to optimize exposure in bone tissue."	( Daptomycin Physiology-Based Pharmacokinetic Modeling to Predict Drug Exposure and Pharmacodynamics in Skin and Bone Tissues. Bourguignon, L; Ferry, T; Garreau, R; Goutelle, S; Grillon, A; Jehl, F; Montange, D, 2022)	0.72
" In obese patients, daptomycin dosage adjustment with total body-weight and adjusted body-weight may lead to an apparent excessive exposure resulting in overdosage compared to lean body-weight."	( Characterization of plasma daptomycin in patients with serum highly glycated albumin and obesity. Imoto, Y; Kawakami, J; Miyadera, Y; Naito, T; Yagi, T; Yamada, T, 2023)	0.91
"No studies exploring the efficacy of routine daptomycin TDM on patient-centred outcomes in comparison with fixed dosing regimens have been published to date."	( The impact of daptomycin therapeutic drug monitoring on clinical outcomes: a systematic review. Abbott, IJ; Cairns, KA; Dooley, MJ; Peel, TN; Peleg, AY; Udy, AA, 2023)	0.91
" An aim of the study includes evaluation of PK of daptomycin in Japanese pediatric patients and an appropriateness of the age-specific, weight-based dosing regimens in Japanese pediatric patients based on PK comparison with Japanese adult patients."	( Pharmacokinetics of intravenous daptomycin in Japanese pediatric patients: Pharmacokinetic comparisons supporting dosing recommendations in Japanese pediatric patients. Ishii, M; Orito, Y; Shiomi, M; Wrishko, RE; Yoshitsugu, H, 2023)	0.91
"Following administration of the age-specific, weight-based dosing regimens, daptomycin exposures were overlapping across age groups in pediatric patients with cSSTI with similar observations based on clearance."	( Pharmacokinetics of intravenous daptomycin in Japanese pediatric patients: Pharmacokinetic comparisons supporting dosing recommendations in Japanese pediatric patients. Ishii, M; Orito, Y; Shiomi, M; Wrishko, RE; Yoshitsugu, H, 2023)	0.91
"The results suggested that the age-specific, weight-based dosing regimens are considered to be appropriate in Japanese pediatric patients."	( Pharmacokinetics of intravenous daptomycin in Japanese pediatric patients: Pharmacokinetic comparisons supporting dosing recommendations in Japanese pediatric patients. Ishii, M; Orito, Y; Shiomi, M; Wrishko, RE; Yoshitsugu, H, 2023)	0.91
" However, more robust research is required to establish an optimal dosing regimen, duration of therapy, and place in therapy for the management of meningitis."	( Daptomycin for the treatment of acute bacterial meningitis: A narrative review. Beahm, NP; Jaber, RH, 2023)	0.91
" This study aimed to evaluate dosing regimens for coadministration of daptomycin and ceftaroline in special populations including paediatrics, renally impaired (RI), obese and geriatrics that generate sufficient coverage against daptomycin-resistant MRSA."	( Physiologically based pharmacokinetic modelling to inform combination dosing regimens of ceftaroline and daptomycin in special populations. Annaert, P; Martins, FS; Martins, JES; Severino, P; Sy, SKB, 2023)	0.91
"The adult dosing regimens of 6 mg/kg every (q)24h or q48h daptomycin and 300-600 mg q12h ceftaroline fosamil by RI categories achieved ≥90% joint PTA when the minimum inhibitory concentrations in the combination are at or below 1 and 4 μg/mL against MRSA."	( Physiologically based pharmacokinetic modelling to inform combination dosing regimens of ceftaroline and daptomycin in special populations. Annaert, P; Martins, FS; Martins, JES; Severino, P; Sy, SKB, 2023)	0.91
"Our work illustrates how physiologically based pharmacokinetic modelling can inform appropriate dosing of adult and paediatric patients and thereby enable prediction of target attainment in the patients during multitherapies."	( Physiologically based pharmacokinetic modelling to inform combination dosing regimens of ceftaroline and daptomycin in special populations. Annaert, P; Martins, FS; Martins, JES; Severino, P; Sy, SKB, 2023)	0.91
"Few drug dosing recommendations for patients receiving home hemodialysis (HHD) have been published which has hindered the adoption of HHD."	( Vancomycin and daptomycin dosing recommendations in patients receiving home hemodialysis using Monte Carlo simulation. Jang, SM; Lewis, SJ; Mueller, BA, 2023)	0.91
"HHD frequency, total dialysate volumes and HHD durations influenced drug exposure and led to different dosing regimens to meet targets."	( Vancomycin and daptomycin dosing recommendations in patients receiving home hemodialysis using Monte Carlo simulation. Jang, SM; Lewis, SJ; Mueller, BA, 2023)	0.91

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	81 (3.68)	18.7374
1990's	74 (3.36)	18.2507
2000's	500 (22.71)	29.6817
2010's	1240 (56.31)	24.3611
2020's	307 (13.94)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	75 (3.31%)	5.53%
Reviews	261 (11.52%)	6.00%
Case Studies	337 (14.87%)	4.05%
Observational	26 (1.15%)	0.25%
Other	1,567 (69.15%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (94)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
[NCT01212432]	Phase 2	15 participants (Anticipated)	Interventional	2009-12-31	Recruiting
A Phase II Open-Label, Single-arm Clinical Trial to Study the Safety, Efficacy and Pharmacokinetics of MK-3009 (Daptomycin) in Japanese Pediatric Participants Aged 1 to 17 Years With Complicated Skin and Soft Tissue Infections or Bacteremia Caused by Gram [NCT03643952]	Phase 2	18 participants (Actual)	Interventional	2018-12-06	Completed
Daptomycin Use For Prophylaxis In Prosthetic Joint Surgery, A Randomized Prospective Study Comparing The Efficacy Of Daptomycin Versus Vancomycin For Peri-Operative Antibiotic Prophylaxis In MRSA Colonized Adult Patients Undergoing Primary Elective Hip, K [NCT01196169]	Phase 4	28 participants (Actual)	Interventional	2010-10-31	Terminated(stopped due to The study is closed to accrual. Enrollment of new patients stopped at the request of CUBIST Pharmaceuticals due to slow rate of enrollment.)
Comparison of the Pharmacokinetic and the Safety of Daptomycin Administered Subcutaneously Compared to the Intravenous Route : a Cross-over Study [NCT04434300]	Phase 1	12 participants (Actual)	Interventional	2020-10-15	Completed
A Randomized, Double-Blind Study Comparing Three Dosing Regimens of Brilacidin to Daptomycin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) [NCT02052388]	Phase 2	215 participants (Actual)	Interventional	2014-02-28	Completed
Open Label, Single Center Study to Evaluate Higher Doses of Daptomycin in the Treatment of Patients With Severe Necrotizing Skin and Soft Tissue Infections. [NCT00261807]		25 participants (Actual)	Interventional	2005-06-30	Completed
Prospective Randomised Study of Daptomycin as Antibiotic Prophylaxis of Sternal Wound Infections After Median Sternotomy [NCT01080963]	Phase 4	650 participants (Actual)	Interventional	2008-11-30	Completed
Acute Kidney Injury During Daptomycin Versus Vancomycin Treatment in Cardiovascular Critically Ill Patients: a Propensity Score Matched Analysis [NCT03961503]		72 participants (Actual)	Observational	2016-01-01	Completed
The Pharmacokinetics and Pharmacodynamics of High-dose Daptomycin in Patients With Septic Shock [NCT02508350]		12 participants (Anticipated)	Interventional	2015-01-31	Recruiting
Utility Assessment of a Pharmacy-to-Dose Daptomycin Protocol: A Retrospective Cohort Study [NCT05224687]		100 participants (Anticipated)	Observational	2021-12-15	Enrolling by invitation
[NCT02142075]	Phase 3	0 participants	Interventional	2014-03-31	Completed
Randomized, Dose Ranging, Active Controlled Efficacy and Safety Evaluation of PMX-30063 As Initial Treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Caused by Staphylococcus Aureus [NCT01211470]	Phase 2	215 participants (Actual)	Interventional	2010-10-31	Completed
Efficacy and Safety of Daptomycin (With or Without Rifampin) in the Treatment of Staphylococcal Hip, Knee and Shoulder Prosthetic Joint Infection [NCT01144000]	Phase 2	60 participants (Anticipated)	Interventional	2012-06-30	Not yet recruiting
Adjunction of Daptomycin for the Treatment of Pneumococcal Meningitis: AddaMAP Study [NCT03480191]	Phase 2	128 participants (Anticipated)	Interventional	2018-06-07	Recruiting
Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL) [NCT05156437]	Phase 4	20 participants (Anticipated)	Interventional	2022-03-16	Enrolling by invitation
Daptomycin Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-venous Hemodiafiltration, a Dose Find Study [NCT01171547]	Phase 2	15 participants (Anticipated)	Interventional	2010-02-28	Recruiting
Application of Daptomycin in MRSA Infected Diabetic Foot in Comparison to Vancomycin Treatment [NCT01199783]	Phase 3	1 participants (Actual)	Interventional	2011-07-31	Terminated(stopped due to Patient number to be enrolled not reachable in prospected time frame, decision to stop the study prematurely was made.)
Dalbavancin For The Treatment Of Gram Positive Osteomyelitis Or Joint Infections Including Prosthetic Hip Or Knee Infections [NCT03426761]	Phase 4	41 participants (Actual)	Interventional	2018-01-25	Completed
A Two Cohort, Open Label, Single and Multiple Dose Pharmacokinetic Study of 4mg/Kg and 6mg/Kg Doses of Daptomycin in Healthy Chinese Subjects Living in China [NCT00858325]	Phase 1	24 participants (Actual)	Interventional	2009-02-28	Completed
Comparing Oral Versus Parenteral Antimicrobial Therapy (COPAT) Trial [NCT05977868]	Phase 4	135 participants (Anticipated)	Interventional	2023-08-04	Enrolling by invitation
Influence of Rifampin Co-Administration on the Pharmacokinetic Profile of Daptomycin [NCT02097953]	Early Phase 1	12 participants (Actual)	Interventional	2014-05-31	Completed
Dalbavancin as an Option for Treatment of S. Aureus Bacteremia (DOTS): A Phase 2b, Multicenter, Randomized, Open-Label, Assessor-Blinded Superiority Study to Compare the Efficacy and Safety of Dalbavancin to Standard of Care Antibiotic Therapy for the Com [NCT04775953]	Phase 2	200 participants (Actual)	Interventional	2021-04-22	Active, not recruiting
Phase II, Open-Label Study to Evaluate the Safety and Efficacy of Daptomycin in the Treatment of Catheter-Related Gram Positive Bloodstream Infections [NCT00467272]	Phase 2	30 participants (Actual)	Interventional	2007-03-31	Completed
A Phase 2 Multicenter, Randomized, Double-blinded, Study to Describe the Safety, Efficacy, and Pharmacokinetics of Daptomycin 10 mg/kg/Day and Vancomycin for the Treatment of Methicillin-resistant Staphylococcus Aureus Bacteremia [NCT00695903]	Phase 2	38 participants (Actual)	Interventional	2008-09-17	Terminated(stopped due to terminated due to lack of enrollment)
A Multicenter, Randomized, Assessor-Blind Study to Evaluate Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections (cSSTI) [NCT00430937]	Phase 3	194 participants (Actual)	Interventional	2006-04-30	Terminated
A Multi-center Prospective Randomized Open Label Study of Utilizing Interleukin 10 (IL-10) Levels as a Guide for Antibiotic Selection for Methicillin Resistant Staphylococcus Aureus Bacteremia [NCT02660346]	Phase 4	40 participants (Actual)	Interventional	2015-11-30	Completed
A Multicentre, Open Label, Uncontrolled Clinical Trial to Evaluate Efficacy and Safety of Daptomycin for the Treatment of Complicated Skin and Skin-Structure Infections (cSSTI) Caused by Methicillin-resistant Staphylococcus Aureus (MRSA) [NCT00463801]	Phase 4	52 participants (Actual)	Interventional	2007-01-31	Terminated(stopped due to Because of inadequate accrual.)
Cubicin(R) for Complicated Post-surgical Wound Infections [NCT00651131]	Phase 4	69 participants (Actual)	Interventional	2004-06-01	Terminated(stopped due to terminated due to slow enrollment)
An Evaluation of the Pharmacokinetic Profile and Safety and Tolerability of Multiple Doses of 6mg/kg Intravenous Daptomycin in Non-Infected Adult Subjects With End Stage Renal Disease on Hemodialysis or Continuous Ambulatory Peritoneal Dialysis [NCT00490737]	Phase 1	12 participants (Actual)	Interventional	2007-08-12	Completed
A Prospective, Randomized, Crossover-design Study to Evaluate the Pharmacokinetics and Safety of Daptomycin Administered at 9 mg/kg During and 6 mg/kg After Hemodialysis [NCT00882557]	Phase 1	16 participants (Actual)	Interventional	2009-04-29	Completed
An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged Two to Six Years Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Gram-positive Infection [NCT00679835]	Phase 1	24 participants (Actual)	Interventional	2008-06-03	Completed
Ceftriaxone as Home Intravenous Therapy for Deep-Seated Staphylococcal Infections, a Randomized Non-Inferiority Trial [NCT04141787]	Phase 4	310 participants (Anticipated)	Interventional	2019-07-11	Recruiting
Prospective Study Evaluating Plasma Exposure of Optimized Antibiotic Therapy According to TDM in Patients With Subarachnoid Haemorrhage (ES) and Cerebral Haemorrhage (EC) [NCT04132115]		104 participants (Anticipated)	Observational	2019-10-01	Recruiting
An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged 3 Months to Twenty-Four Months Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Bacterial Infection Includi [NCT01019395]	Phase 1	23 participants (Actual)	Interventional	2010-01-05	Completed
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci [NCT01191840]	Phase 2	509 participants (Actual)	Interventional	2011-02-28	Completed
The Influence Factors of Pharmacokinetics/Pharmacodynamics of Daptomycin in Severe Patients and the the Effect of Different Blood Concentration of Daptomycin on the Outcomes of Renal Function [NCT04277143]		120 participants (Anticipated)	Observational	2020-12-01	Not yet recruiting
A Phase 3, Multicentre, Randomised, Investigator-blinded, Parallel-groupStudy of the Safety and Efficacy of Intravenous Daptomycin (Cubicin®)Compared With That of Comparator (Vancomycin or Vancomycin Followed by Semi-synthetic Penicillin-cloxacillin) in t [NCT00772447]	Phase 3	265 participants (Actual)	Interventional	2008-09-30	Completed
Randomized Multicenter Study to Assess Efficacy of Daptomycin Plus Fosfomycin Versus Daptomycin Monotherapy for Treatment of Methicillin Resistant Staphylococcus Aureus Bacteremia in Hospitalized Patients [NCT01898338]	Phase 3	167 participants (Actual)	Interventional	2013-12-31	Completed
Pharmacokinetics Study of Intraperitoneal Administration of Daptomycin in Patients With Peritoneal Dialysis and Peritoneal Infection [NCT02000414]		8 participants (Actual)	Interventional	2013-09-30	Completed
A Phase 2 Randomized Study Investigating the Safety, Efficacy and Pharmacokinetics of Daptomycin 6 mg/kg and 8 mg/kg Versus Comparator in the Treatment of Subjects Undergoing Surgical Standard of Care for Osteomyelitis Associated With an Infected Prosthet [NCT00428844]	Phase 2	75 participants (Actual)	Interventional	2007-06-26	Completed
Open Label Study to Assess the Efficacy and Safety of Daptomycin in Combination With Anti-Cell Wall Active Therapy in the Treatment of Enterococcal Endocarditis [NCT00401960]	Phase 4	6 participants (Actual)	Interventional	2006-09-30	Terminated(stopped due to inadequate enrollment)
A Multi-centre Open Label Randomized Controlled Phase IIB Trial Comparing Vancomycin Versus Daptomycin for the Treatment of MRSA Bacteremia Due to Isolates With High Vancomycin Minimum Inhibitory Concentrations [NCT01975662]	Phase 2	14 participants (Actual)	Interventional	2014-01-31	Terminated(stopped due to slow accrual of participants)
Non-interventional Observational Study of Daptomycin in the Treatment of Gram-positive Bacterial Infections [NCT04546815]		2,000 participants (Anticipated)	Observational	2020-08-25	Recruiting
A Phase 4, Prospective, Randomized, Open-label Study to Compare Use of Cubicin With Vancomycin Administered Intravenously in the Treatment of Patients With Complicated Skin and Skin Structure Infections Due to Suspected or Confirmed Gram-positive Bacteria [NCT01175707]	Phase 4	80 participants (Actual)	Interventional	2010-07-15	Terminated(stopped due to Business decision)
An Evaluation of the Safety, Efficacy and Pharmacokinetics of Daptomycin in Pediatric Subjects Aged One to Seventeen Years With Complicated Skin and Skin Structure Infections Caused by Gram-Positive Pathogens [NCT00711802]	Phase 4	396 participants (Actual)	Interventional	2008-07-23	Completed
An Open Label, Multi-center, Randomized, Comparative Phase IIIb Study to Compare Efficacy and Safety of Intravenous (i.v.) Daptomycin With That of Semi-Synthetic Penicillins (SSPs) or Vancomycin in the Treatment of Elderly Patients (Aged ≥ 65 Years) With [NCT01184872]	Phase 3	120 participants (Actual)	Interventional	2010-03-31	Completed
A Randomized, Double-Blind, Phase III, Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae [NCT00538694]	Phase 3	0 participants	Interventional	2000-10-31	Completed
An Investigator Initiated, Phase IV Single-Center, Randomized, Open-Label, Prospective Study to Determine the Impact of Serial Procalcitonin on Improving Antimicrobial Stewardship and on the Efficacy, Safety, and Tolerability of Imipenem - Relebactam Plus [NCT04983901]	Phase 2	100 participants (Actual)	Interventional	2021-09-14	Active, not recruiting
A Phase 3, Multicenter, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of Daptomycin Compared to Conventional Therapy In the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to Staph Aureus [NCT00093067]	Phase 3	0 participants	Interventional	2002-03-31	Completed
[NCT01756924]	Phase 2	14 participants (Actual)	Interventional	2012-12-31	Terminated(stopped due to This study has been terminated; alternative study designs are being considered. Fusidic acid remains available under an Expanded Access Protocol.)
A Prospective, Multicenter, Randomized, Evaluator-blinded, Comparator-controlled Study to Describe the Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin Structure Infections (cSSSI) and Staphylococcus Aureus Bacteremia Among [NCT01104662]	Phase 4	92 participants (Actual)	Interventional	2010-04-19	Terminated(stopped due to Cubist has reached an agreement with the FDA that enrollment in the DAP-RENSE-08-05 study can stop.)
A Phase III Randomized, Open-labeled Clinical Trial of MK-3009 (Daptomycin) in Patients With Skin and Soft Tissue Infections, Septicemia and Right-sided Infective Endocarditis Caused by MRSA [NCT00770341]	Phase 3	122 participants (Actual)	Interventional	2008-09-30	Completed
Pharmacokinetics and Toxicodynamics of Daptomycin in Bone and Joint Infections [NCT04933344]		1,130 participants (Anticipated)	Observational	2021-06-15	Recruiting
[NCT01287832]	Phase 4	11 participants (Actual)	Interventional	2011-06-30	Terminated(stopped due to Low patient enrollment)
[NCT00540072]	Phase 3	0 participants	Interventional	2001-07-30	Completed
Antibiotic Plasma Concentrations During Continuous Renal Replacement Therapy With a High Adsorption Membrane (oXiris®) [NCT04033029]		20 participants (Actual)	Observational	2021-01-01	Completed
Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease [NCT01012089]		6 participants (Actual)	Interventional	2009-11-30	Completed
An Open Label Phase 4 Trial to Further Evaluate the Pharmacokinetic Profile of Intravenous Daptomycin, and a Comparison of the Safety and Efficacy of Daptomycin Versus Comparator in the Treatment of Adult Patients With Renal Impairment and Complicated Ski [NCT00102947]	Phase 4	72 participants	Interventional	2005-01-31	Terminated
An Evaluation of the Pharmacokinetics of a Single Dose of Daptomycin (4 mg/kg) in Pediatric Patients Aged Two to Seventeen Years Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Gram-positive Infection [NCT00136292]	Phase 1	33 participants (Actual)	Interventional	2005-08-24	Completed
Phase II, Open-Label Study to Evaluate the Safety and Efficacy of Daptomycin in the Treatment of Catheter-Related Staphylococcus Aureus Bloodstream Infections [NCT00507247]	Phase 2	11 participants (Actual)	Interventional	2006-05-31	Completed
A Randomized, Multicenter Trial of Daptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated Methicillin-resistant Staphylococcus Aureus Bacteremia [NCT01515020]	Phase 3	10 participants (Actual)	Interventional	2012-05-31	Terminated(stopped due to lack of inclusion)
Evaluation of Cerebrospinal Fluid Concentration of Daptomycin (Cubicin¬) in Pediatric Patients With Gram-positive Bacterial Meningitis, Concurrently Receiving Standard Antimicrobial Therapy [NCT01522105]	Phase 1	1 participants (Actual)	Interventional	2012-04-30	Terminated(stopped due to Insufficient patient recruitment)
Clinical Usefulness of Mic/Breakpoint Ratio and Penetration in Tissues. A Prospective Study of Clinical Validation [NCT01551719]		0 participants (Actual)	Interventional	2012-03-31	Withdrawn
A Compassionate Use Protocol for Intravenous Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria That Cannot be Adequately Treated With Currently Available Therapy [NCT00055198]	Phase 3	75 participants	Interventional	2002-12-19	Terminated(stopped due to Study terminated due to low enrollment)
Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery [NCT00701636]	Phase 3	30 participants (Actual)	Interventional	2008-07-31	Completed
Pharmacokinetics of Daptomycin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD) [NCT00663403]	Phase 4	8 participants (Actual)	Interventional	2007-02-28	Completed
An Open-Label, Pilot Study of Daptomycin vs. Vancomycin for Treatment of Gram-Positive Bacteremia in Neutropenic Cancer Patients [NCT00296049]		0 participants (Actual)	Interventional	2005-07-31	Withdrawn
A Multicenter, Randomized Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in the Treatment of Cellulitis or Erysipelas [NCT00295178]	Phase 4	80 participants	Interventional	2006-02-20	Completed
[NCT00451373]		300 participants	Interventional	2006-07-31	Recruiting
Effects of Daptomycin in the Levels of IL-1, IL-6 and TNF in Patients With Complicated Cellulitis/Erisipela in Comparison With Vancomycin or Oxacillin [NCT01626560]	Phase 4	20 participants (Actual)	Interventional	2012-07-31	Completed
Early Oral Switch Therapy in Low-risk Staphylococcus Aureus Bloodstream Infection [NCT01792804]	Phase 3	215 participants (Actual)	Interventional	2013-12-31	Completed
Cerebrospinal Fluid Pharmacokinetics of Daptomycin [NCT01025271]		2 participants (Actual)	Interventional	2010-05-31	Terminated(stopped due to unable to enroll subjects study stopped due to lack of enrollment)
Evaluation of Single-dose Pharmacokinetics of Intravenous Daptomycin in Patients With Thermal Injury [NCT02241941]	Phase 4	0 participants (Actual)	Interventional	2014-09-30	Withdrawn(stopped due to Assessment of daptomycin concentrations with microdialysis technically not feasible)
An Open Label Study to Describe the Pharmacokinetics of Daptomycin in Infants [NCT00942149]	Phase 1	20 participants (Actual)	Interventional	2010-01-31	Completed
A Pilot Study of Daptomycin for Antimicrobial Prophylaxis in Patients Undergoing Cardiac Valve Replacement and Coronary Artery Bypass Grafting (CABG) Who Are at Increased Risk for Infection Due to Methicillin-resistant Staphylococcus Aureus (MRSA) [NCT00572260]	Phase 4	11 participants (Actual)	Interventional	2008-01-31	Terminated(stopped due to Study closed. PI left the institution.)
Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients [NCT01734694]	Phase 4	100 participants (Actual)	Interventional	2011-10-31	Terminated(stopped due to Independent biostatistician recommended early termination of the trial due to low probability of success.)
Concentration and Antibiotic Activity in Antibiotic Lock Solutions [NCT01592032]	Phase 4	125 participants (Anticipated)	Interventional	2012-05-31	Active, not recruiting
A Single Center, Double-Blind, Randomized, Comparative Study to Evaluate the Efficacy and Safety of Daptomycin Versus Placebo in Patients With Neutropenia and Fever. [NCT01216241]	Phase 3	36 participants (Actual)	Interventional	2011-04-30	Terminated(stopped due to The study has shown futility and the objectives could not be reached without enrolling a very large number of subjects.)
Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis: an Open, Randomized, Controlled Clinical Trial [NCT01455246]	Phase 2/Phase 3	32 participants (Actual)	Interventional	2010-10-31	Terminated(stopped due to Decision of independent monitoring committee after interim analysis: Risk of failure significantly higher in ceftazidime group.)
Phase II Open Label Pilot Trial of Empiric Daptomycin Treatment for Oncology Patients With Neutropenic Fever [NCT00335478]	Phase 2	54 participants (Actual)	Interventional	2006-12-31	Completed
Phase 2 Multicenter Randomized Semi-Single Blind Study to Compare Efficacy and Safety of High-dose Short Duration Daptomycin With Conventional Therapy in Complicated Skin and Skin Structure Infections Due to Gram-positive Bacteria [NCT00426933]	Phase 2	100 participants (Actual)	Interventional	2007-01-31	Completed
Daptomycin as Adjunctive Therapy for Staphylococcus Aureus Bacteremia [NCT02972983]	Phase 4	102 participants (Actual)	Interventional	2016-12-01	Completed
Daptomycin Concentration in Drainage Fluid and Blood Samples of ICU Patients [NCT03004066]		9 participants (Actual)	Observational	2016-10-31	Completed
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus. [NCT01728376]	Phase 4	82 participants (Actual)	Interventional	2012-11-29	Completed
Evaluation of Daptomycin for the Emergency Department Treatment of Complicated Skin and Skin Structure Infections [NCT01549613]	Phase 4	104 participants (Actual)	Interventional	2012-05-31	Completed
Retrospective Effectiveness Study of Dalbavancin and Other Standard of Care of the Same Class (i.v. Lipo and Glyco-peptides) in Patients With ABSSSI [NCT04298463]		184 participants (Actual)	Observational	2020-06-18	Completed
Description of Eosinophilic Pneumonia in BJI/PJI Treated by Daptomycin [NCT04414137]		20 participants (Anticipated)	Observational	2019-02-19	Recruiting
A Multicenter, Randomized, Double-Blinded Comparative Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daptomycin Versus Active Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis Due to Gram-Positive Organisms [NCT01922011]	Phase 3	149 participants (Actual)	Interventional	2013-09-13	Completed
Staphylococcus Aureus Network Adaptive Platform Trial [NCT05137119]	Phase 4	6,000 participants (Anticipated)	Interventional	2022-02-16	Recruiting
A Phase 4 Multicenter, Randomized, Double Blind Study to Describe the Efficacy and Safety of Cubicin® (Daptomycin for Injection) With and Without Initial Gentamicin Combination Therapy in the Treatment of S. Aureus Infective Endocarditis [NCT00638157]	Phase 4	24 participants (Actual)	Interventional	2009-02-13	Terminated(stopped due to commitment completed)
A Randomized Study to Evaluate Comparative Effectiveness, Inpatient Resource Utilization, and Cost of Daptomycin vs. Vancomycin in the Treatment of Patients With Complicated Skin and Skin Structure Infections Due to Suspected or Documented Methicillin-res [NCT01419184]	Phase 4	250 participants (Actual)	Interventional	2011-09-09	Completed
A Randomized, Double-blind, Multi-center Study to Establish the Efficacy and Safety of Ceftobiprole Medocaril Compared to Daptomycin in the Treatment of Staphylococcus Aureus Bacteremia, Including Infective Endocarditis [NCT03138733]	Phase 3	390 participants (Actual)	Interventional	2018-08-26	Completed
A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy in the Treatment of Subjects With Staphylococcus Aureus Bacteremia Including Infective Endocarditis [NCT02208063]	Phase 3	121 participants (Actual)	Interventional	2014-12-31	Terminated(stopped due to Halted due to lack of statistical power. No safety concerns identified.)
Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for the Treatment of Diabetic Foot Osteomyelitis (CRO-OSTEOMYELITIS) [NCT02168816]	Phase 2	30 participants (Actual)	Interventional	2014-03-19	Terminated(stopped due to The study was stopped for feasibility (i.e., low recruitment))
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00261807 (3) [back to overview]	Clinical Response to High Dose Daptomycin Therapy at End of Treatment (EOT)
NCT00261807 (3) [back to overview]	Clinical Response to High Dose Daptomycin Therapy at Test of Cure (TOC)
NCT00261807 (3) [back to overview]	Microbiological Response to High Dose Daptomycin Therapy at End of Treatment (EOT) and Test of Cure (TOC)
NCT00335478 (1) [back to overview]	Number of Participants Who Became Afebrile Within 72 Hours of Starting Daptomycin.
NCT00401960 (2) [back to overview]	Number of Participants With Any Grade 3 or 4 Toxicity (DAIDS Scale)
NCT00401960 (2) [back to overview]	Number of Participants With Muscle Toxicity or Renal Toxicity, as Determined by Predefined Criteria
NCT00428844 (6) [back to overview]	Any Creatine Phosphokinase (CPK) Elevation > 500 Units Per Liter (U/L)
NCT00428844 (6) [back to overview]	Pharmacokinetic Parameter: Area Under the Concentration-time Curve During a Dosing Interval at Steady State (AUCss)
NCT00428844 (6) [back to overview]	Pharmacokinetic Parameter: Maximum Plasma Concentration (Cmax)
NCT00428844 (6) [back to overview]	Microbiological Response
NCT00428844 (6) [back to overview]	Overall Clinical Outcome
NCT00428844 (6) [back to overview]	Safety - Notable Laboratory Abnormalities
NCT00430937 (2) [back to overview]	Microbiological Efficacy Measured by the Number of Participants Achieving Bacteriological Eradication of Gram-positive Baseline Pathogens at the TOC Visit.
NCT00430937 (2) [back to overview]	"Clinical Success as Measured by Comparing the Participants Signs and Symptoms at the Test of Cure (TOC) Visit to Those Recorded at Study Baseline in the Clinically Evaluable Population."
NCT00463801 (1) [back to overview]	Proportion of Participants With Clinical Success at the Day 7 (D7) and Day 14 (D14) Visit After Treatment Start
NCT00467272 (6) [back to overview]	Clinical Response Within 48 Hours
NCT00467272 (6) [back to overview]	Clinical Response Within 7 Days
NCT00467272 (6) [back to overview]	Microbiological Response Within 48 Hours
NCT00467272 (6) [back to overview]	Microbiological Response Within 7 Days
NCT00467272 (6) [back to overview]	Number of Participants With Overall Response
NCT00467272 (6) [back to overview]	Relapse
NCT00638157 (2) [back to overview]	Summary of the Investigator's Assessment of Clinical Response at the TOC Visit
NCT00638157 (2) [back to overview]	Summary of Clinically Significant Increases in Serum Creatinine by Visit
NCT00663403 (7) [back to overview]	Daptomycin Volume of Distribution at Steady State
NCT00663403 (7) [back to overview]	Daptomycin Transmembrane Clearance by Continuous Venovenous Hemodialysis
NCT00663403 (7) [back to overview]	Daptomycin Total Body Clearance
NCT00663403 (7) [back to overview]	Daptomycin Half-life
NCT00663403 (7) [back to overview]	Daptomycin Free Fraction
NCT00663403 (7) [back to overview]	Daptomycin Dose Actually Administered
NCT00663403 (7) [back to overview]	Observed Daptomycin Peak Serum Concentration
NCT00695903 (4) [back to overview]	Number of Participants With Treatment Cure at End of Therapy (EOT) Visit
NCT00695903 (4) [back to overview]	Number of Participants With Treatment Cure at Test of Cure (TOC)/Safety Visit
NCT00695903 (4) [back to overview]	Number of Participants With Treatment-emergent Creatine Phosphokinase (CPK) Elevations
NCT00695903 (4) [back to overview]	Number of Participants With Elevated Serum Creatinine
NCT00701636 (1) [back to overview]	Mean Daptomycin Concentrations at 12, 18, 24, and 48 h
NCT00711802 (3) [back to overview]	Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
NCT00711802 (3) [back to overview]	Percentage of Participants With an Overall Therapeutic Response at Test of Cure Visit
NCT00711802 (3) [back to overview]	Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve for Daptomycin From 0 to the Last Sampling Time Point (AUC[0-t])
NCT00770341 (6) [back to overview]	Efficacy Adjudication Committee (EAC) Assessment of Number of Participants With Microbiological Response at TOC
NCT00770341 (6) [back to overview]	Efficacy Adjudication Committee (EAC) Assessment of Number of Participants With Clinical Success at Test of Cure (TOC)
NCT00770341 (6) [back to overview]	EAC Assessment of Number of Participants With Microbiological Response at End of Treatment (EOT).
NCT00770341 (6) [back to overview]	EAC Assessment of Number of Participants With Clinical Success at End of Treatment (EOT).
NCT00770341 (6) [back to overview]	Study Investigators' Assessment of Clinical Response at TOC
NCT00770341 (6) [back to overview]	Study Investigators' Assessment of Clinical Response at EOT
NCT00772447 (12) [back to overview]	Blinded Investigator's Assessement of Clinical Response at EOT(End of Therapy)
NCT00772447 (12) [back to overview]	Blinded Investigator's Assessement of Clinical Response at TOC(Test of Cure)
NCT00772447 (12) [back to overview]	Change in Creatinine Clearance
NCT00772447 (12) [back to overview]	Change in Serum Total Creatine Phosphokinase (CPK)
NCT00772447 (12) [back to overview]	Change in Urine pH
NCT00772447 (12) [back to overview]	Change of Erythrocyte Volume Fraction(Percentage of Erythrocyte Volume in Total Volume of Blood)
NCT00772447 (12) [back to overview]	Microbiological Response at EOT(End of Therapy)
NCT00772447 (12) [back to overview]	Microbiological Response at TOC(Test of Cure)
NCT00772447 (12) [back to overview]	Per-pathogen(Methicillin Resistant Staphylococcus Aureus) Clinical Response at TOC(Test of Cure)
NCT00772447 (12) [back to overview]	Per-pathogen(Methicillin Sensitive Staphylococcus Aureus) Clinical Response at TOC
NCT00772447 (12) [back to overview]	Per-pathogen(Staphylococcus Aureus) Microbiological Response at TOC
NCT00772447 (12) [back to overview]	Shift in ECG
NCT00882557 (7) [back to overview]	Volume of Distribution
NCT00882557 (7) [back to overview]	Clearance of Daptomycin
NCT00882557 (7) [back to overview]	Evaluation of Area Under the Curve From Time 0 to Infinity
NCT00882557 (7) [back to overview]	Half-life
NCT00882557 (7) [back to overview]	Maximum Plasma Concentration
NCT00882557 (7) [back to overview]	Time to Maximum Concentration
NCT00882557 (7) [back to overview]	Treatment-emergent Adverse Events
NCT00942149 (1) [back to overview]	PK of Daptomycin
NCT01012089 (8) [back to overview]	Maximum Plasma Concentration (Cmax)
NCT01012089 (8) [back to overview]	Elimination Rate Constant (Ke)
NCT01012089 (8) [back to overview]	Drug Clearance Due to Dialysis (CLdialysis)
NCT01012089 (8) [back to overview]	Area Under the Concentration Time Curve From Time Zero to 48 Hours (AUC0-48)
NCT01012089 (8) [back to overview]	Area Under the Concentration Time Curve From Time Zero to 24 Hours (AUC0-24)
NCT01012089 (8) [back to overview]	Area Under the Concentration Time Curve From Time Zero to Infinity (AUC0-∞)
NCT01012089 (8) [back to overview]	Total Drug Clearance (CLtotal)
NCT01012089 (8) [back to overview]	Volume of Distribution at Steady State (Vss)
NCT01104662 (2) [back to overview]	Overall Therapeutic Outcome at Test of Cure (TOC)/Safety Visit
NCT01104662 (2) [back to overview]	Number of Participants With Treatment-emergent Creatine Phosphokinase (CPK) Elevations Through End of Therapy/Early Termination (EOT/ET)
NCT01175707 (15) [back to overview]	Time Spent (Minutes) for Home Infusion Therapy
NCT01175707 (15) [back to overview]	Reasons for Pharmacist Consultations During Home Infusion Therapy
NCT01175707 (15) [back to overview]	Number of Nurse Visits or Consultations Per Participant for Home Infusion Therapy
NCT01175707 (15) [back to overview]	Reasons for Nurse Visits During Home Infusion Therapy
NCT01175707 (15) [back to overview]	Health Economic Outcomes in United States (US) Dollars for Home Infusion Therapy Per Participant
NCT01175707 (15) [back to overview]	Mean Number of Interventions Per Participant During Home Infusion Therapy
NCT01175707 (15) [back to overview]	Number of Intervention Types During Home Infusion Therapy
NCT01175707 (15) [back to overview]	Number of Laboratory Assessment Types During Home Infusion Therapy
NCT01175707 (15) [back to overview]	Number of Participants With at Least 1 Intervention Related to Complicated Skin or Skin Structure Infection (cSSSI) During Home Infusion Therapy
NCT01175707 (15) [back to overview]	Total Antibiotic Therapy Duration (in Days) Per Participant for Home Infusion Therapy
NCT01175707 (15) [back to overview]	Percentage of Treatment Goals Met at End of Therapy
NCT01175707 (15) [back to overview]	Participants Who Had More Than 1 Laboratory Assessment During Home Infusion Therapy
NCT01175707 (15) [back to overview]	Number of Participants With at Least One Pharmacist Consultation During Home Infusion Therapy
NCT01175707 (15) [back to overview]	Number of Participants With at Least 1 Unscheduled Nursing Visit During Home Infusion Therapy
NCT01175707 (15) [back to overview]	Mean Number of Laboratory Assessments Per Participant During Home Infusion Therapy
NCT01184872 (5) [back to overview]	Number of Patients With Clinical Success at the Test-Of-Cure (TOC) Visit
NCT01184872 (5) [back to overview]	Number of Patients With Adverse Events, Serious Adverse Events and Death
NCT01184872 (5) [back to overview]	Number of Participants With Microbiological Response at Test-of-Cure (TOC) Visit
NCT01184872 (5) [back to overview]	Duration of Treatment (Intravenous)
NCT01184872 (5) [back to overview]	Duration of Treatment (Intravenous and Oral)
NCT01191840 (5) [back to overview]	Antibiotic Days by Treatment Group
NCT01191840 (5) [back to overview]	Cure Rate
NCT01191840 (5) [back to overview]	Number of Participants With Serious Adverse Events
NCT01191840 (5) [back to overview]	Number of Participants With Adverse Events Leading to Study Drug Withdrawal
NCT01191840 (5) [back to overview]	Number of Participants That Changed From Vancomycin to Another Study Antibiotic Due to an Adverse Event
NCT01216241 (1) [back to overview]	Percentage of Afebrile Neutropenic Subjects
NCT01287832 (1) [back to overview]	Number of Participants With Clinical Success at Test of Cure Visit.
NCT01419184 (6) [back to overview]	Participant Global Impression of Improvement (PGI-I) at Hospital Discharge
NCT01419184 (6) [back to overview]	30-day cSSSI-related Hospital Readmission Rates
NCT01419184 (6) [back to overview]	Infection-Related Hospital Length of Stay
NCT01419184 (6) [back to overview]	Mean Change From Baseline to Hospital Discharge in Pain According to the Brief Pain Inventory-Short Form (BPI-SF)
NCT01419184 (6) [back to overview]	Mean Change From Baseline to Hospital Discharge in Participant-reported Health-related Quality of Life (HRQoL)
NCT01419184 (6) [back to overview]	cSSSI-related Medical Resource Utilization and Costs
NCT01549613 (1) [back to overview]	Satisfaction of Discharge Criteria
NCT01728376 (9) [back to overview]	Percentage of Participants With Overall Success at TOC Visit
NCT01728376 (9) [back to overview]	Percentage of Participants With Sustained CPK Elevations
NCT01728376 (9) [back to overview]	Trough Plasma Concentration of Daptomycin
NCT01728376 (9) [back to overview]	Number of Participants With One or More Serious Adverse Events (SAEs)
NCT01728376 (9) [back to overview]	Number of Participants With Abnormal Focused (Peripheral) Neurological Assessments at Test of Cure (TOC)
NCT01728376 (9) [back to overview]	Percentage of Participants With Clinical Success at TOC/Safety Visit
NCT01728376 (9) [back to overview]	Maximum Plasma Concentration (Cmax) of Daptomycin
NCT01728376 (9) [back to overview]	Number of Participants With One or More Adverse Events (AEs)
NCT01728376 (9) [back to overview]	Percentage of Participants With Maximum Post-Baseline Creatine Phosphokinase (CPK) Elevations Above Upper Limit of Normal
NCT01734694 (2) [back to overview]	Proportion of Individuals With Acute Kidney Injury Network Modified Definition of Nephrotoxicity
NCT01734694 (2) [back to overview]	Proportion of Individuals With Nephrotoxicity
NCT01922011 (13) [back to overview]	Plasma Concentration of Daptomycin at the End of IV Infusion
NCT01922011 (13) [back to overview]	Concentration of Serum Creatine Kinase (CK)
NCT01922011 (13) [back to overview]	Percentage of Participants With a Clinical Cure Categorized by Baseline Pathogen at Test of Cure
NCT01922011 (13) [back to overview]	Percentage of Participants With a Favorable Clinical Outcome
NCT01922011 (13) [back to overview]	Percentage of Participants With a Favorable Microbiological Response Categorized by Baseline Pathogen at Test of Cure
NCT01922011 (13) [back to overview]	Percentage of Participants With Sustained Clinical Improvement
NCT01922011 (13) [back to overview]	Number of Participants With 1 or More Adverse Events (AEs)
NCT01922011 (13) [back to overview]	Number of Participants With 1 or More Serious Adverse Events (SAEs)
NCT01922011 (13) [back to overview]	Percentage of Participants With Clinical Improvement in the 3 General Categories of Pain, Inflammation, and Limb Function Based on the Investigator's Overall Assessment of Severity of Each of the Symptom Categories.
NCT01922011 (13) [back to overview]	Percentage of Participants With Clinical Improvement Measured as a Composite End Point of Pain, Inflammation, Limb Function, Body Temperature, and C-reactive Protein at End-of IV (EOIV) Therapy Visit.
NCT01922011 (13) [back to overview]	Plasma Concentration of Daptomycin at 15 Minutes to 1 Hour After the End of IV Infusion
NCT01922011 (13) [back to overview]	Plasma Concentration of Daptomycin at 2 to 3 Hours After the End of IV Infusion
NCT01922011 (13) [back to overview]	Plasma Concentration of Daptomycin at 4 to 5 Hours After the End of IV Infusion
NCT02208063 (4) [back to overview]	Investigator Clinical Response (Success or Failure) at EOT in the Microbiological All-treated (mAT) Population
NCT02208063 (4) [back to overview]	Number of Participants With a Clinical Outcome of Cure at Test of Cure (TOC)
NCT02208063 (4) [back to overview]	Number of Participants With an Investigator Clinical Outcome of Cure at TOC in the Microbiological All-treated (mAT) Population
NCT02208063 (4) [back to overview]	Number of Participants With the Development of a New Metastatic Foci of S. Aureus Infection at Test of Cure (TOC) in the Microbiological All-treated (mAT) Populations
NCT03138733 (6) [back to overview]	Number of Patients With Microbiological Eradication at the PTE Visit
NCT03138733 (6) [back to overview]	Time to Staphylococcus Aureus Bloodstream Clearance
NCT03138733 (6) [back to overview]	All-cause Mortality at the PTE Visit
NCT03138733 (6) [back to overview]	Number of Patients With or Without Adverse Events (AEs)
NCT03138733 (6) [back to overview]	Number of Patients With or Without Overall Success at the Post-treatment Evaluation (PTE) Visit
NCT03138733 (6) [back to overview]	Number of Patients With or Without Overall Success at the PTE Visit in the CE Population
NCT03643952 (16) [back to overview]	Maximum Plasma Concentration (Cmax) of Daptomycin
NCT03643952 (16) [back to overview]	Body Weight Adjusted Clearance (CLss/wt) of Daptomycin
NCT03643952 (16) [back to overview]	Body Weight Adjusted Clearance (CLss/wt) of Daptomycin
NCT03643952 (16) [back to overview]	Area Under the Concentration Time Curve From 0 to 24 Hours (AUC0-24hr) of Daptomycin
NCT03643952 (16) [back to overview]	Area Under the Concentration Time Curve From 0 to 24 Hours (AUC0-24hr) of Daptomycin
NCT03643952 (16) [back to overview]	Apparent Terminal Half-Life (t½) of Daptomycin
NCT03643952 (16) [back to overview]	Apparent Terminal Half-Life (t½) of Daptomycin
NCT03643952 (16) [back to overview]	Percentage of Participants With MRSA Infections Who Experienced a Microbiological Response
NCT03643952 (16) [back to overview]	Percentage of Participants With Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Who Experienced Clinical Success
NCT03643952 (16) [back to overview]	Time to Maximum Plasma Concentration (Tmax) of Daptomycin
NCT03643952 (16) [back to overview]	Percentage of Participants That Discontinued Study Treatment Due to an Adverse Event (AE)
NCT03643952 (16) [back to overview]	Volume of Distribution at Steady State (Vss) of Daptomycin
NCT03643952 (16) [back to overview]	Volume of Distribution at Steady State (Vss) of Daptomycin
NCT03643952 (16) [back to overview]	Time to Maximum Plasma Concentration (Tmax) of Daptomycin
NCT03643952 (16) [back to overview]	Percentage of Participants With an Adverse Event
NCT03643952 (16) [back to overview]	Maximum Plasma Concentration (Cmax) of Daptomycin

Clinical Response to High Dose Daptomycin Therapy at End of Treatment (EOT)

"Clinical response was assessed by measuring impact of therapy on certain wound parameters. Specifically Erythema, Induration/Swelling, Suppuration, were recorded visually and WBC Counts were considered improved if <12,000/cu mm.~The clinical response was documented as:~CURE (resolution of clinical signs and symptoms and no additional need for gram-positive antibiotic therapy.~IMPROVED (partial resolution of clinical signs and symptoms (although patient's clinical status had not completely returned to preinfection baseline but infectious process had been controlled , no additional gram-positive antibiotic therapy was needed;~FAILURE (no response, worsening of clinical signs and symptoms of infection; or additional gram-positive antibiotic therapy was needed );~UNABLE TO EVALUATE (unable to determine response; e.g., no evaluation performed at specified time points, or administration of non-study antibiotics effective against study pathogen)." (NCT00261807)
Timeframe: The clinical response was measured at the end of treatment (7-14 days)

Intervention	Participants (Count of Participants)
	Erythema-EOT72552002				Induration EOT72552002	Suppuration-EOT72552002	WBC Counts EOT72552002
	Improved	Failure	Unable to Evaluate	Cure
Single ARM Study	16
Single ARM Study	2
Single ARM Study	17
Single ARM Study	1
Single ARM Study	0
Single ARM Study	13
Single ARM Study	5
Single ARM Study	18

Intervention	Participants (Count of Participants)
	Erythema-TOC72552003				Induration TOC72552003	Suppuration72552003	WBC Counts-TOC72552003
	Failure	Unable to Evaluate	Cure	Improved
Single ARM Study	18
Single ARM Study	0

Intervention	Participants (Count of Participants)
	End of Therapy72552002			Test of Cure72552002
	Presumed Eradicated	Documented Eradicated	Documented Persistent
Single ARM Study	23
Single ARM Study	18
Single ARM Study	0

Intervention	Participants (Count of Participants)
	Elevated serum creatinine >= 30% above baseline	Elevate serum creatine kinase > 3X ULN
Daptomycin Adjunctive Group	1	0
Standard of Care	1	0

Intervention	Participants (Number)
	Success	Failure	Non-evaluable
Comparator	8	6	7
Daptomycin 6 mg/kg	12	8	4
Daptomycin 8 mg/kg	12	3	8

Intervention	Participants (Number)
	Success	Failure	Nonevaluable
Comparator	8	11	2
Daptomycin 6 mg/kg	13	10	1
Daptomycin 8 mg/kg	13	8	2

Intervention	Participants (Number)
	Hematocrit (<30%, >60%)	Hemoglobin (<9,>19 g/dL)	Red Blood Cell (Female <2.5,>6.0; Male <3.0, >6.5)	White Blood Cell (<2, >20 x 10^9/L)	Platelets (<40, >450 x 10^9/L)	Albumin (<3, >6 g/dL)	Alkaline Phosphatase (>1350 U/L)	Alanine aminotransferase (>235 U/L)	Aspartate aminotransferase (>185 U/L)	Total bilirubin (>2.2 mg/dL)	Blood Urea Nitrogen (>50 mg/dL)	Creatinine (Female >2.0; Male>2.8 mg/dL)
Comparator	15	12	3	0	10	4	0	0	0	0	1	2
Daptomycin 6 mg/kg	12	10	2	1	13	7	0	0	1	0	2	1
Daptomycin 8 mg/kg	10	10	4	0	13	4	0	0	0	0	0	0

Intervention	Participants (Number)
	Microbiological Success	Microbiological Failure
Daptomycin	56	1
Pooled Comparator	39	4

Intervention	Participants (Number)
	Clinical Success	Clinical Failure
Daptomycin	53	5
Pooled Comparator	41	6

Intervention	Participants (Number)
	TC (clinical cure, microbiological success)	TC (clinical cure, microbiological nonevaluable)	TF (clinical failure, microbiological success)	TF (clinical cure, microbiological failure)	TF (clinical failure, microbiological failure)	TF (clinical improved, microbiological failure)	TF (clinical failure, microbiological nonevaluable	TI (clinical improved, microbiological success)	TI (clin improved, microbiological nonevaluable)	Non-evaluable
Daptomycin	4	0	1	0	2	0	0	0	0	2
Daptomycin Plus Gentamicin	5	0	1	0	0	0	2	1	0	2

Intervention	Participants (Number)
	Baseline - Any Elevation	Baseline - No Elevation	End of Therapy - Any Elevation	End of Therapy - No Elevation	Test of Cure - Any Elevation (n=8,9)	Test of Cure - No Elevation (n=8,9)
Daptomycin	0	10	0	10	0	8
Daptomycin Plus Gentamicin	0	12	2	10	2	7

Intervention	mcg/ml (Mean)
	mean daptomycin concentration at 12 hours	mean daptomycin concentration at 18 hours	mean daptomycin concentration at 24 hours	mean daptomycin concentration at 48 hours
Cases	22.7	16.2	12.0	3.5

Intervention	percentage of participants (Number)
	At least 1 TEAE	At least 1 drug-related TEAE	Discontinued treatment due to a TEAE
Age Group 1: Daptomycin	36.1	13.9	2.8
Age Group 1: Standard of Care (SOC)	36.8	10.5	0
Age Group 2: Daptomycin	23.3	5.5	1.4
Age Group 2: SOC	18.4	10.5	0
Age Group 3: Daptomycin	50.6	22.2	3.7
Age Group 3: SOC	38.1	21.4	14.3
Age Group 4: Daptomycin	46.7	10.0	3.3
Age Group 4: SOC	73.3	33.3	6.7

Intervention	Participants (Number)
MK-3009 (Daptomycin) 4 mg/kg	31
Vancomycin	9
MK-3009 (Daptomycin) 6 mg/kg	2

Intervention	Percentage of patients (Number)
Daptomycin	90.9
Vancomycin, or Vancomycin Switch to Cloxacillin	91.3

Intervention	percentage of patients (Number)
Daptomycin	93.5
Vancomycin, or Vancomycin Switch to Cloxacillin	90.1

Intervention	ml/min (Mean)
Daptomycin	9.91
Vancomycin, or Vancomycin Switch to Cloxacillin	0.99

Intervention	IU/L (Mean)
Daptomycin	0.60
Vancomycin, or Vancomycin Switch to Cloxacillin	-2.40

Intervention	pH (Mean)
Daptomycin	-0.19
Vancomycin, or Vancomycin Switch to Cloxacillin	-0.30

Intervention	percentage (Mean)
Daptomycin	0.00
Vancomycin, or Vancomycin Switch to Cloxacillin	0.01

Intervention	Percentage of strains (Number)
Daptomycin	89.5
Vancomycin, or Vancomycin Switch to Cloxacillin	87.5

daptomycin

Cross-References

Synonyms (4)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Research

Studies (2,202)

Study Types

Clinical Trials (94)

Trial Overview

Trial Outcomes

Clinical Response to High Dose Daptomycin Therapy at End of Treatment (EOT)

Clinical Response to High Dose Daptomycin Therapy at Test of Cure (TOC)

Microbiological Response to High Dose Daptomycin Therapy at End of Treatment (EOT) and Test of Cure (TOC)

Number of Participants Who Became Afebrile Within 72 Hours of Starting Daptomycin.

Number of Participants With Any Grade 3 or 4 Toxicity (DAIDS Scale)

Number of Participants With Muscle Toxicity or Renal Toxicity, as Determined by Predefined Criteria

Any Creatine Phosphokinase (CPK) Elevation > 500 Units Per Liter (U/L)

Pharmacokinetic Parameter: Area Under the Concentration-time Curve During a Dosing Interval at Steady State (AUCss)

Pharmacokinetic Parameter: Maximum Plasma Concentration (Cmax)

Microbiological Response

Overall Clinical Outcome

Safety - Notable Laboratory Abnormalities

Microbiological Efficacy Measured by the Number of Participants Achieving Bacteriological Eradication of Gram-positive Baseline Pathogens at the TOC Visit.

"Clinical Success as Measured by Comparing the Participants Signs and Symptoms at the Test of Cure (TOC) Visit to Those Recorded at Study Baseline in the Clinically Evaluable Population."

Proportion of Participants With Clinical Success at the Day 7 (D7) and Day 14 (D14) Visit After Treatment Start

Clinical Response Within 48 Hours

Clinical Response Within 7 Days

Microbiological Response Within 48 Hours

Microbiological Response Within 7 Days

Number of Participants With Overall Response

Relapse

Summary of the Investigator's Assessment of Clinical Response at the TOC Visit

Summary of Clinically Significant Increases in Serum Creatinine by Visit

Daptomycin Volume of Distribution at Steady State

Daptomycin Transmembrane Clearance by Continuous Venovenous Hemodialysis

Daptomycin Total Body Clearance

Daptomycin Half-life

Daptomycin Free Fraction

Daptomycin Dose Actually Administered

Observed Daptomycin Peak Serum Concentration

Number of Participants With Treatment Cure at End of Therapy (EOT) Visit

Number of Participants With Treatment Cure at Test of Cure (TOC)/Safety Visit

Number of Participants With Treatment-emergent Creatine Phosphokinase (CPK) Elevations

Number of Participants With Elevated Serum Creatinine

Mean Daptomycin Concentrations at 12, 18, 24, and 48 h

Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

Percentage of Participants With an Overall Therapeutic Response at Test of Cure Visit

Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve for Daptomycin From 0 to the Last Sampling Time Point (AUC[0-t])

Efficacy Adjudication Committee (EAC) Assessment of Number of Participants With Microbiological Response at TOC

Efficacy Adjudication Committee (EAC) Assessment of Number of Participants With Clinical Success at Test of Cure (TOC)

EAC Assessment of Number of Participants With Microbiological Response at End of Treatment (EOT).

EAC Assessment of Number of Participants With Clinical Success at End of Treatment (EOT).

Study Investigators' Assessment of Clinical Response at TOC

Study Investigators' Assessment of Clinical Response at EOT

Blinded Investigator's Assessement of Clinical Response at EOT(End of Therapy)

Blinded Investigator's Assessement of Clinical Response at TOC(Test of Cure)

Change in Creatinine Clearance

Change in Serum Total Creatine Phosphokinase (CPK)

Change in Urine pH

Change of Erythrocyte Volume Fraction(Percentage of Erythrocyte Volume in Total Volume of Blood)

Microbiological Response at EOT(End of Therapy)

Microbiological Response at TOC(Test of Cure)

Per-pathogen(Methicillin Resistant Staphylococcus Aureus) Clinical Response at TOC(Test of Cure)

Per-pathogen(Methicillin Sensitive Staphylococcus Aureus) Clinical Response at TOC

Per-pathogen(Staphylococcus Aureus) Microbiological Response at TOC

Shift in ECG

Volume of Distribution

Clearance of Daptomycin

Evaluation of Area Under the Curve From Time 0 to Infinity

Half-life

Maximum Plasma Concentration

Time to Maximum Concentration

Treatment-emergent Adverse Events

PK of Daptomycin

Maximum Plasma Concentration (Cmax)

Intervention	Percentage of strains (Number)
Daptomycin	94.0
Vancomycin, or Vancomycin Switch to Cloxacillin	90.7

Intervention	Percentage of patients (Number)
Daptomycin	91.7
Vancomycin, or Vancomycin Switch to Cloxacillin	87.5

Intervention	mL/kg (Median)
6 mg/kg After Hemodialysis (Regimen B)	137
9 mg/kg During Hemodialysis (Regimen A)	145

Intervention	mL/hr/kg (Median)
6 mg/kg After Hemodialysis (Regimen B)	3.54
9 mg/kg During Hemodialysis (Regimen A)	3.32

Intervention	hr*ug/mL (Median)
6 mg/kg After Hemodialysis (Regimen B)	1692
9 mg/kg During Hemodialysis (Regimen A)	2708

Intervention	Hours (Median)
6 mg/kg After Hemodialysis (Regimen B)	29.8
9 mg/kg During Hemodialysis (Regimen A)	31.1

Intervention	ug/mL (Median)
6 mg/kg After Hemodialysis (Regimen B)	70.5
9 mg/kg During Hemodialysis (Regimen A)	100

Intervention	Hours (Median)
6 mg/kg After Hemodialysis (Regimen B)	0.50
9 mg/kg During Hemodialysis (Regimen A)	0.50

Intervention	mg/L (Mean)
Daptomycin Hemodialysis	42.4
Daptomycin Peritoneal Dialysis	66.5

Intervention	hr-1 (Mean)
Daptomycin Hemodialysis	0.0053
Daptomycin Peritoneal Dialysis	0.00848